Search Results For:
- No search criteria provided
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
Aridis-PATH Vaccine Formulation Agreement
2007
Biotechnology company
Product development partnership
Product development partnership
Vaccine
Early clinical (through Phase 2)
- Access to medicines | Equitable access
- Access to medicines | Equitable access
- Access to medicines | Affordable or reasonable pricing
- Information sharing & data safety | Confidentiality
- IP ownership & licensing | Exploitation of results
- IP ownership & licensing | Ownership of results
- IP ownership & licensing | Protection of results
- IP ownership & licensing | Sublicenses
- Liability | Limitation of liability/damage
- Term & termination | Effect of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
AUTM Model Inter-Institutional Agreement
2015
Academic institution
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Business model | Benefit/revenue sharing
- Consortium structure & management
- Information sharing & data safety | Confidentiality
- IP ownership & licensing | Exceptions or limitations to the IP ownership rules
- IP ownership & licensing | Exploitation of results
- IP ownership & licensing | Protection of results
- Liability | Limitation of liability/damage
- Liability | Warranties
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Boston University Startup Exclusive License
2012
Academic institution
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
CARB-X Research Subaward Agreement (for-profit)
2019
Funder
General Industry
General Industry
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
CAVD Data & Materials Sharing Agreement
2006
Academic institution
Funder
General Industry
Government
Other nonprofit
Funder
General Industry
Government
Other nonprofit
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Data management
- Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
- Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
- Information sharing & data safety | Information sharing
- IP ownership & licensing | Ownership of background IP
- IP ownership & licensing | Use of background IP
CEPI CfP3i Template Funding Agreement
2018
Funder
Vaccine
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
- Access to medicines | Equitable access
- Access to medicines | Equitable access
- Access to medicines | Equitable access
- Access to medicines | Equitable access
- Access to medicines | Public health licenses
- Business model | Benefit/revenue sharing
- IP ownership & licensing | Ownership of results
- IP ownership & licensing | Protection of results
- Open sciences & open data | Open data
- Open sciences & open data | Open data
- Open sciences & open data | Open sciences
- Open sciences & open data | Publication
Collaboration and License Agreement between Sanofi and Translate Bio, as Amended
2020
Biotechnology company
Multinational pharmaceutical company
Multinational pharmaceutical company
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
- Access to medicines | Pandemic Products
- Business model | Royalties & payments
- Information sharing & data safety | Technology transfer
- Information sharing & data safety | Technology transfer
- IP ownership & licensing | Ownership of results
- Open sciences & open data | Publication
- Other | Dispute resolution
- Term & termination | Termination & withdrawal
Ebola WHO-Manufacturer LOA (Annex)
2015
Multilateral organization
Drug
Vaccine
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Early clinical (through Phase 2)
Late clinical (Phase 3)
EDCTP2 Policy on Clinical Trials
2018
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Late clinical (Phase 3)
Funder Development Partnering Agreement
2018
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Access to medicines | Equitable access
- Access to medicines | Equitable access
- Access to medicines | Equitable access
- Access to medicines | Funder step-in rights
- Access to medicines | Outbreak preparedness
- Business model | Benefit/revenue sharing
- IP ownership & licensing | Access to results
- IP ownership & licensing | Exploitation of results
- IP ownership & licensing | Ownership of results
- IP ownership & licensing | Protection of results
- IP ownership & licensing | Use of background IP
- Liability | Limitation of liability/damage
Gates Foundation Open Access Policy
2015
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Gates Foundation Sample Terms & Conditions
2019
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Gilead-Indian Manufacturers HCV License Agreement
2014
Multinational pharmaceutical company
Pharmaceutical manufacturer
Pharmaceutical manufacturer
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Global Access Commitment & Humanitarian License
2018
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
IMI 1 Model Grant Agreement
2011
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
IMI 2 JU Model Consortium Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Consortium structure & management
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Data management
- Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
- Information sharing & data safety | Material transfer
- IP ownership & licensing
- IP ownership & licensing | Exploitation of results
- IP ownership & licensing | Exploitation of results
- IP ownership & licensing | Ownership of background IP
- IP ownership & licensing | Ownership of results
- IP ownership & licensing | Protection of results
- IP ownership & licensing | Use of background IP
- Liability | Indemnity / indemnification
- Liability | Limitation of liability/damage
- Liability | Warranties
IMI 2 Model Grant Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Consortium structure & management
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
- IP ownership & licensing | Access to results
- IP ownership & licensing | Access to results
- IP ownership & licensing | Exploitation of results
- IP ownership & licensing | Ownership of background IP
- IP ownership & licensing | Ownership of results
- IP ownership & licensing | Protection of results
- IP ownership & licensing | Use of background IP
- IP ownership & licensing | Use of background IP
- IP ownership & licensing | Use of background IP
- Liability | Limitation of liability/damage
- Open sciences & open data | Open data
Lambert Agreement D
2019
Academic institution
General Industry
General Industry
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Consortium structure & management
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Data management
- Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
- Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
- IP ownership & licensing | Exploitation of results
- IP ownership & licensing | Ownership of background IP
- IP ownership & licensing | Ownership of results
- IP ownership & licensing | Use of background IP
- Liability | Indemnity / indemnification
- Liability | Limitation of liability/damage
- Liability | Warranties
- Open sciences & open data | Open sciences
- Open sciences & open data | Publication
- Term & termination | Termination & withdrawal
Merck-BSC License Collaboration Agreement
2014
Biotechnology company
Multinational pharmaceutical company
Multinational pharmaceutical company
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
- Information sharing & data safety | Technology transfer
- IP ownership & licensing | Ownership of background IP
- IP ownership & licensing | Ownership of results
- IP ownership & licensing | Protection of results
- IP ownership & licensing | Use of background IP
- Liability | Indemnity / indemnification
- Liability | Limitation of liability/damage
- Term & termination | Effect of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
MPP-AbbVie License Agreement (LPV r)
2016
Multinational pharmaceutical company
Other nonprofit
Other nonprofit
Drug
Commercialization
MPP-AbbVie Sublicense Agreement
2014
Multinational pharmaceutical company
Other nonprofit
Other nonprofit
Drug
Commercialization
MPP-BMS-Aurobindo Sublicense Agreement
2016
Multinational pharmaceutical company
Other nonprofit
Pharmaceutical manufacturer
Other nonprofit
Pharmaceutical manufacturer
Drug
Commercialization
MPP-BMS Sublicense & Tech Transfer Agreement
2017
Multinational pharmaceutical company
Other nonprofit
Other nonprofit
Drug
Commercialization
MPP-Gilead License Agreement
2011
Multinational pharmaceutical company
Other nonprofit
Other nonprofit
Drug
Commercialization
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Technology transfer
- IP ownership & licensing | Access to results
- IP ownership & licensing | Ownership of results
- IP ownership & licensing | Use of background IP
- Liability | Indemnity / indemnification
- Liability | Limitation of liability/damage
MPP-Pfizer License Agreement (Sutezolid)
2019
Multinational pharmaceutical company
Other nonprofit
Other nonprofit
Drug
Commercialization
MPP-Univ. of Liverpool License Agreement
2015
Academic institution
Other nonprofit
Other nonprofit
Device
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
MPP-ViiV License Agreement
2016
Multinational pharmaceutical company
Other nonprofit
Other nonprofit
Drug
Commercialization
NIH Model License Agreement for Use by Non-Profit
2017
Government
Other nonprofit
Product development partnership
Other nonprofit
Product development partnership
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Redacted Collaboration Agreement
2016
Academic institution
General Industry
General Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Information sharing & data safety
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Data management
- Information sharing & data safety | Information sharing
- Information sharing & data safety | Material transfer
- IP ownership & licensing | Ownership of results
- Open sciences & open data | Open data
- Open sciences & open data | Open sciences
- Open sciences & open data | Publication
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Ten Principles for Socially Responsible Licensing
2019
Academic institution
Drug
Vaccine
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Mutual Confidential Disclosure Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Project Collaboration Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Standard Framework MoU
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Template Collaboration Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Template Material Transfer Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Material transfer
- Information sharing & data safety | Material transfer
- Information sharing & data safety | Technology transfer
- IP ownership & licensing | Ownership of background IP
- Liability | Indemnity / indemnification
GHIAA2019\MapguideSearch Object
(
[search_parameters] =>
[filters] => Array
(
)
[child_filters] => Array
(
)
[agreement_args] =>
[provision_args] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
)
[text_agreement_args] =>
[text_provision_args] =>
[agreement_ids] => Array
(
)
[agreement_q_rslts] =>
[provision_q_rslts] => WP_Query Object
(
[query] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
)
[query_vars] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[suppress_filters] =>
[ignore_sticky_posts] =>
[cache_results] => 1
[update_post_term_cache] => 1
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] => 1
[comments_per_page] => 50
[no_found_rows] =>
[order] => DESC
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wpry_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT wpry_posts.* FROM wpry_posts WHERE 1=1 AND wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled') ORDER BY wpry_posts.post_date DESC
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 2425
[post_author] => 5
[post_date] => 2020-12-14 15:02:33
[post_date_gmt] => 2020-12-14 15:02:33
[post_content] =>
[post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-12-22 10:41:23
[post_modified_gmt] => 2020-12-22 10:41:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2425
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 2426
[post_author] => 5
[post_date] => 2020-12-14 15:02:08
[post_date_gmt] => 2020-12-14 15:02:08
[post_content] =>
[post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-12-22 13:52:16
[post_modified_gmt] => 2020-12-22 13:52:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2426
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 2424
[post_author] => 5
[post_date] => 2020-12-14 15:01:40
[post_date_gmt] => 2020-12-14 15:01:40
[post_content] =>
[post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-12-22 13:51:02
[post_modified_gmt] => 2020-12-22 13:51:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2424
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 2422
[post_author] => 5
[post_date] => 2020-12-14 14:59:29
[post_date_gmt] => 2020-12-14 14:59:29
[post_content] =>
[post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended
[to_ping] =>
[pinged] =>
[post_modified] => 2020-12-22 10:43:20
[post_modified_gmt] => 2020-12-22 10:43:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2422
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 1395
[post_author] => 7
[post_date] => 2020-05-30 21:25:33
[post_date_gmt] => 2020-05-30 21:25:33
[post_content] =>
[post_title] => Gates Foundation Sample Terms & Conditions for Project Support Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-sample-terms-conditions-for-project-support-grant-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:28:33
[post_modified_gmt] => 2020-08-06 08:28:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1395
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 1394
[post_author] => 7
[post_date] => 2020-05-30 21:22:44
[post_date_gmt] => 2020-05-30 21:22:44
[post_content] =>
[post_title] => Gates Foundation Sample Terms & Conditions for Project Support Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-sample-terms-conditions-for-project-support-grant-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:40:24
[post_modified_gmt] => 2020-08-06 05:40:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1394
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 1393
[post_author] => 7
[post_date] => 2020-05-30 20:13:50
[post_date_gmt] => 2020-05-30 20:13:50
[post_content] =>
[post_title] => Gates Foundation Open Access Policy
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 1393
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 04:49:54
[post_modified_gmt] => 2020-08-06 04:49:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1393
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 1315
[post_author] => 7
[post_date] => 2020-05-23 17:56:03
[post_date_gmt] => 2020-05-23 17:56:03
[post_content] =>
[post_title] => MPP License Agreement with ViiV on Dolutegravir for Adults
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-viiv-on-dolutegravir-for-adults-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-10-10 22:05:56
[post_modified_gmt] => 2020-10-10 22:05:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1315
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 1313
[post_author] => 7
[post_date] => 2020-05-23 17:55:00
[post_date_gmt] => 2020-05-23 17:55:00
[post_content] =>
[post_title] => MPP Sublicense Agreement under AbbVie-MPP License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-04 05:11:03
[post_modified_gmt] => 2020-08-04 05:11:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1313
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 1314
[post_author] => 7
[post_date] => 2020-05-23 17:54:57
[post_date_gmt] => 2020-05-23 17:54:57
[post_content] =>
[post_title] => MPP Amended and Restated Sublicense and Technology Transfer Agreement under BMS-MPP License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-10-10 22:08:33
[post_modified_gmt] => 2020-10-10 22:08:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1314
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 1308
[post_author] => 7
[post_date] => 2020-05-23 17:17:48
[post_date_gmt] => 2020-05-23 17:17:48
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 04:59:05
[post_modified_gmt] => 2020-08-06 04:59:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1308
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 1309
[post_author] => 7
[post_date] => 2020-05-23 17:17:44
[post_date_gmt] => 2020-05-23 17:17:44
[post_content] =>
[post_title] => IMI 2Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2joint-undertaking-model-consortium-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 04:59:37
[post_modified_gmt] => 2020-08-06 04:59:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1309
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 1311
[post_author] => 7
[post_date] => 2020-05-23 17:12:09
[post_date_gmt] => 2020-05-23 17:12:09
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:43:06
[post_modified_gmt] => 2020-08-06 05:43:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1311
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 1310
[post_author] => 7
[post_date] => 2020-05-23 17:12:02
[post_date_gmt] => 2020-05-23 17:12:02
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:30:05
[post_modified_gmt] => 2020-08-06 08:30:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1310
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 1307
[post_author] => 7
[post_date] => 2020-05-23 17:05:21
[post_date_gmt] => 2020-05-23 17:05:21
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2020-10-10 22:20:30
[post_modified_gmt] => 2020-10-10 22:20:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1307
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 1306
[post_author] => 7
[post_date] => 2020-05-23 16:57:14
[post_date_gmt] => 2020-05-23 16:57:14
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:45:45
[post_modified_gmt] => 2020-08-06 05:45:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1306
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 1305
[post_author] => 7
[post_date] => 2020-05-23 16:51:40
[post_date_gmt] => 2020-05-23 16:51:40
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 1305
[to_ping] =>
[pinged] =>
[post_modified] => 2020-10-10 22:21:50
[post_modified_gmt] => 2020-10-10 22:21:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1305
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 1304
[post_author] => 7
[post_date] => 2020-05-23 16:46:37
[post_date_gmt] => 2020-05-23 16:46:37
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:47:49
[post_modified_gmt] => 2020-08-06 05:47:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1304
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 1303
[post_author] => 7
[post_date] => 2020-05-23 16:46:30
[post_date_gmt] => 2020-05-23 16:46:30
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:48:31
[post_modified_gmt] => 2020-08-06 05:48:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1303
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 1296
[post_author] => 6
[post_date] => 2020-05-22 23:46:47
[post_date_gmt] => 2020-05-22 23:46:47
[post_content] =>
[post_title] => WHO
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:49:42
[post_modified_gmt] => 2020-08-06 05:49:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1296
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 1291
[post_author] => 6
[post_date] => 2020-05-22 23:42:19
[post_date_gmt] => 2020-05-22 23:42:19
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm
[to_ping] =>
[pinged] =>
[post_modified] => 2020-10-10 22:25:11
[post_modified_gmt] => 2020-10-10 22:25:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1291
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 1293
[post_author] => 6
[post_date] => 2020-05-22 23:42:02
[post_date_gmt] => 2020-05-22 23:42:02
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-13
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:50:33
[post_modified_gmt] => 2020-08-06 05:50:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1293
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 1288
[post_author] => 6
[post_date] => 2020-05-22 23:31:30
[post_date_gmt] => 2020-05-22 23:31:30
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:15:24
[post_modified_gmt] => 2020-08-06 19:15:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1288
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 1287
[post_author] => 6
[post_date] => 2020-05-22 23:05:30
[post_date_gmt] => 2020-05-22 23:05:30
[post_content] =>
[post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation).
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-10
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-07 14:11:07
[post_modified_gmt] => 2020-08-07 14:11:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1287
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[24] => WP_Post Object
(
[ID] => 1285
[post_author] => 6
[post_date] => 2020-05-22 23:01:07
[post_date_gmt] => 2020-05-22 23:01:07
[post_content] =>
[post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation).
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:55:08
[post_modified_gmt] => 2020-08-06 05:55:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1285
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[25] => WP_Post Object
(
[ID] => 1284
[post_author] => 6
[post_date] => 2020-05-22 22:58:55
[post_date_gmt] => 2020-05-22 22:58:55
[post_content] =>
[post_title] => Aridis-PATH Vaccine Formulation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:55:57
[post_modified_gmt] => 2020-08-06 05:55:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1284
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[26] => WP_Post Object
(
[ID] => 1283
[post_author] => 6
[post_date] => 2020-05-22 22:57:44
[post_date_gmt] => 2020-05-22 22:57:44
[post_content] =>
[post_title] => Aridis-PATH Vaccine Formulation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:56:15
[post_modified_gmt] => 2020-08-06 05:56:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1283
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[27] => WP_Post Object
(
[ID] => 1282
[post_author] => 6
[post_date] => 2020-05-22 22:56:18
[post_date_gmt] => 2020-05-22 22:56:18
[post_content] =>
[post_title] => Redacted Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:56:57
[post_modified_gmt] => 2020-08-06 05:56:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1282
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[28] => WP_Post Object
(
[ID] => 1281
[post_author] => 6
[post_date] => 2020-05-22 22:55:22
[post_date_gmt] => 2020-05-22 22:55:22
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-12
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:57:24
[post_modified_gmt] => 2020-08-06 05:57:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1281
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[29] => WP_Post Object
(
[ID] => 1280
[post_author] => 6
[post_date] => 2020-05-22 22:54:32
[post_date_gmt] => 2020-05-22 22:54:32
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-iia-7
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:57:59
[post_modified_gmt] => 2020-08-06 05:57:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1280
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[30] => WP_Post Object
(
[ID] => 1276
[post_author] => 6
[post_date] => 2020-05-22 22:40:34
[post_date_gmt] => 2020-05-22 22:40:34
[post_content] =>
[post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-8
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:58:18
[post_modified_gmt] => 2020-08-06 05:58:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1276
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[31] => WP_Post Object
(
[ID] => 1275
[post_author] => 6
[post_date] => 2020-05-22 22:39:41
[post_date_gmt] => 2020-05-22 22:39:41
[post_content] =>
[post_title] => Aridis-PATH Vaccine Formulation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:58:40
[post_modified_gmt] => 2020-08-06 05:58:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1275
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[32] => WP_Post Object
(
[ID] => 1274
[post_author] => 6
[post_date] => 2020-05-22 22:38:47
[post_date_gmt] => 2020-05-22 22:38:47
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:59:08
[post_modified_gmt] => 2020-08-06 05:59:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1274
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[33] => WP_Post Object
(
[ID] => 1273
[post_author] => 6
[post_date] => 2020-05-22 22:37:54
[post_date_gmt] => 2020-05-22 22:37:54
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-iia-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-04 04:20:47
[post_modified_gmt] => 2020-08-04 04:20:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1273
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[34] => WP_Post Object
(
[ID] => 1272
[post_author] => 6
[post_date] => 2020-05-22 22:36:39
[post_date_gmt] => 2020-05-22 22:36:39
[post_content] =>
[post_title] => BU Startup Exclusive License
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bu-startup-exclusive-license-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:59:41
[post_modified_gmt] => 2020-08-06 05:59:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1272
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[35] => WP_Post Object
(
[ID] => 1271
[post_author] => 6
[post_date] => 2020-05-22 22:34:12
[post_date_gmt] => 2020-05-22 22:34:12
[post_content] =>
[post_title] => WHO Standard Framework Memorandum of Understanding
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-standard-framework-memorandum-of-understanding-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:00:10
[post_modified_gmt] => 2020-08-06 06:00:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1271
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[36] => WP_Post Object
(
[ID] => 1270
[post_author] => 6
[post_date] => 2020-05-22 22:32:29
[post_date_gmt] => 2020-05-22 22:32:29
[post_content] =>
[post_title] => MPP License Agreement with Gilead
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-gilead-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-10-18 11:46:22
[post_modified_gmt] => 2020-10-18 11:46:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1270
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[37] => WP_Post Object
(
[ID] => 1269
[post_author] => 6
[post_date] => 2020-05-22 22:29:54
[post_date_gmt] => 2020-05-22 22:29:54
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-11
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:01:05
[post_modified_gmt] => 2020-08-06 06:01:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1269
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[38] => WP_Post Object
(
[ID] => 1268
[post_author] => 6
[post_date] => 2020-05-22 22:27:54
[post_date_gmt] => 2020-05-22 22:27:54
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:01:30
[post_modified_gmt] => 2020-08-06 06:01:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1268
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[39] => WP_Post Object
(
[ID] => 1267
[post_author] => 6
[post_date] => 2020-05-22 22:26:39
[post_date_gmt] => 2020-05-22 22:26:39
[post_content] =>
[post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-7
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:02:22
[post_modified_gmt] => 2020-08-06 06:02:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1267
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[40] => WP_Post Object
(
[ID] => 1266
[post_author] => 6
[post_date] => 2020-05-22 22:25:16
[post_date_gmt] => 2020-05-22 22:25:16
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:03:25
[post_modified_gmt] => 2020-08-06 06:03:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1266
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[41] => WP_Post Object
(
[ID] => 1265
[post_author] => 6
[post_date] => 2020-05-22 22:24:11
[post_date_gmt] => 2020-05-22 22:24:11
[post_content] =>
[post_title] => WHO Template Material Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-template-material-transfer-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:03:50
[post_modified_gmt] => 2020-08-06 06:03:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1265
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[42] => WP_Post Object
(
[ID] => 1264
[post_author] => 6
[post_date] => 2020-05-22 22:22:55
[post_date_gmt] => 2020-05-22 22:22:55
[post_content] =>
[post_title] => Gilead HCV License Agreement with Indian Generic Manufacturers
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:04:26
[post_modified_gmt] => 2020-08-06 06:04:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1264
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[43] => WP_Post Object
(
[ID] => 1263
[post_author] => 6
[post_date] => 2020-05-22 22:20:56
[post_date_gmt] => 2020-05-22 22:20:56
[post_content] =>
[post_title] => MPP License Agreement with Gilead
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-gilead-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:21:52
[post_modified_gmt] => 2020-08-06 19:21:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1263
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[44] => WP_Post Object
(
[ID] => 1262
[post_author] => 6
[post_date] => 2020-05-22 22:18:41
[post_date_gmt] => 2020-05-22 22:18:41
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-10
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:05:46
[post_modified_gmt] => 2020-08-06 06:05:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1262
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[45] => WP_Post Object
(
[ID] => 1261
[post_author] => 6
[post_date] => 2020-05-22 22:17:34
[post_date_gmt] => 2020-05-22 22:17:34
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:06:36
[post_modified_gmt] => 2020-08-06 06:06:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1261
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[46] => WP_Post Object
(
[ID] => 1259
[post_author] => 6
[post_date] => 2020-05-22 22:04:31
[post_date_gmt] => 2020-05-22 22:04:31
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-9
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:06:50
[post_modified_gmt] => 2020-08-06 06:06:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1259
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[47] => WP_Post Object
(
[ID] => 1258
[post_author] => 6
[post_date] => 2020-05-22 22:03:08
[post_date_gmt] => 2020-05-22 22:03:08
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-8
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:07:40
[post_modified_gmt] => 2020-08-06 06:07:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1258
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[48] => WP_Post Object
(
[ID] => 1257
[post_author] => 6
[post_date] => 2020-05-22 21:54:08
[post_date_gmt] => 2020-05-22 21:54:08
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:08:19
[post_modified_gmt] => 2020-08-06 06:08:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1257
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[49] => WP_Post Object
(
[ID] => 1255
[post_author] => 6
[post_date] => 2020-05-22 21:49:26
[post_date_gmt] => 2020-05-22 21:49:26
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-7
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:09:08
[post_modified_gmt] => 2020-08-06 06:09:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1255
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[50] => WP_Post Object
(
[ID] => 1254
[post_author] => 6
[post_date] => 2020-05-22 21:44:49
[post_date_gmt] => 2020-05-22 21:44:49
[post_content] =>
[post_title] => Gates Foundation Data & Materials Sharing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-data-materials-sharing-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:09:56
[post_modified_gmt] => 2020-08-06 06:09:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1254
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[51] => WP_Post Object
(
[ID] => 1253
[post_author] => 6
[post_date] => 2020-05-22 21:42:28
[post_date_gmt] => 2020-05-22 21:42:28
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:38:41
[post_modified_gmt] => 2020-08-06 19:38:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1253
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[52] => WP_Post Object
(
[ID] => 1252
[post_author] => 6
[post_date] => 2020-05-22 21:41:17
[post_date_gmt] => 2020-05-22 21:41:17
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:25:32
[post_modified_gmt] => 2020-08-06 06:25:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1252
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[53] => WP_Post Object
(
[ID] => 1251
[post_author] => 6
[post_date] => 2020-05-22 21:39:48
[post_date_gmt] => 2020-05-22 21:39:48
[post_content] =>
[post_title] => CAVD Data & Materials Sharing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cavd-data-materials-sharing-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:40:50
[post_modified_gmt] => 2020-08-06 19:40:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1251
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[54] => WP_Post Object
(
[ID] => 1250
[post_author] => 6
[post_date] => 2020-05-22 21:38:31
[post_date_gmt] => 2020-05-22 21:38:31
[post_content] =>
[post_title] => CAVD Data & Materials Sharing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cavd-data-materials-sharing-agreement-2-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:41:55
[post_modified_gmt] => 2020-08-06 19:41:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1250
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[55] => WP_Post Object
(
[ID] => 1249
[post_author] => 6
[post_date] => 2020-05-22 21:37:42
[post_date_gmt] => 2020-05-22 21:37:42
[post_content] =>
[post_title] => MPP License Agreement with Gilead
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-gilead-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:22:26
[post_modified_gmt] => 2020-08-06 06:22:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1249
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[56] => WP_Post Object
(
[ID] => 1248
[post_author] => 6
[post_date] => 2020-05-22 21:36:47
[post_date_gmt] => 2020-05-22 21:36:47
[post_content] =>
[post_title] => Redacted Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:19:18
[post_modified_gmt] => 2020-08-06 06:19:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1248
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[57] => WP_Post Object
(
[ID] => 1247
[post_author] => 6
[post_date] => 2020-05-22 21:33:54
[post_date_gmt] => 2020-05-22 21:33:54
[post_content] =>
[post_title] => WHO Mutual Confidential Disclosure Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-mutual-confidential-disclosure-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:18:47
[post_modified_gmt] => 2020-08-06 06:18:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1247
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[58] => WP_Post Object
(
[ID] => 1245
[post_author] => 6
[post_date] => 2020-05-22 21:32:14
[post_date_gmt] => 2020-05-22 21:32:14
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:17:49
[post_modified_gmt] => 2020-08-06 06:17:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1245
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[59] => WP_Post Object
(
[ID] => 1244
[post_author] => 6
[post_date] => 2020-05-22 21:30:57
[post_date_gmt] => 2020-05-22 21:30:57
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:16:51
[post_modified_gmt] => 2020-08-06 06:16:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1244
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[60] => WP_Post Object
(
[ID] => 1243
[post_author] => 6
[post_date] => 2020-05-22 21:29:10
[post_date_gmt] => 2020-05-22 21:29:10
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-iia-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:15:56
[post_modified_gmt] => 2020-08-06 06:15:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1243
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[61] => WP_Post Object
(
[ID] => 1242
[post_author] => 6
[post_date] => 2020-05-22 21:26:04
[post_date_gmt] => 2020-05-22 21:26:04
[post_content] =>
[post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:45:06
[post_modified_gmt] => 2020-08-06 19:45:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1242
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[62] => WP_Post Object
(
[ID] => 1241
[post_author] => 6
[post_date] => 2020-05-22 21:24:25
[post_date_gmt] => 2020-05-22 21:24:25
[post_content] =>
[post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:13:20
[post_modified_gmt] => 2020-08-06 06:13:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1241
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[63] => WP_Post Object
(
[ID] => 1240
[post_author] => 6
[post_date] => 2020-05-22 21:22:47
[post_date_gmt] => 2020-05-22 21:22:47
[post_content] =>
[post_title] => Aridis-PATH Vaccine Formulation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:11:52
[post_modified_gmt] => 2020-08-06 06:11:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1240
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[64] => WP_Post Object
(
[ID] => 1239
[post_author] => 6
[post_date] => 2020-05-22 21:21:49
[post_date_gmt] => 2020-05-22 21:21:49
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:27:18
[post_modified_gmt] => 2020-08-06 06:27:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1239
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[65] => WP_Post Object
(
[ID] => 1238
[post_author] => 6
[post_date] => 2020-05-22 21:20:51
[post_date_gmt] => 2020-05-22 21:20:51
[post_content] =>
[post_title] => Redacted Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:29:07
[post_modified_gmt] => 2020-08-06 06:29:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1238
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[66] => WP_Post Object
(
[ID] => 1237
[post_author] => 6
[post_date] => 2020-05-22 21:19:08
[post_date_gmt] => 2020-05-22 21:19:08
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:29:51
[post_modified_gmt] => 2020-08-06 06:29:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1237
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[67] => WP_Post Object
(
[ID] => 1236
[post_author] => 6
[post_date] => 2020-05-22 21:17:57
[post_date_gmt] => 2020-05-22 21:17:57
[post_content] =>
[post_title] => WHO Template Material Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-template-material-transfer-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:30:25
[post_modified_gmt] => 2020-08-06 06:30:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1236
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[68] => WP_Post Object
(
[ID] => 1235
[post_author] => 6
[post_date] => 2020-05-22 21:01:14
[post_date_gmt] => 2020-05-22 21:01:14
[post_content] =>
[post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:33:13
[post_modified_gmt] => 2020-08-06 06:33:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1235
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[69] => WP_Post Object
(
[ID] => 1233
[post_author] => 6
[post_date] => 2020-05-22 21:00:08
[post_date_gmt] => 2020-05-22 21:00:08
[post_content] =>
[post_title] => Redacted Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:49:06
[post_modified_gmt] => 2020-08-06 19:49:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1233
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[70] => WP_Post Object
(
[ID] => 1232
[post_author] => 6
[post_date] => 2020-05-22 20:57:46
[post_date_gmt] => 2020-05-22 20:57:46
[post_content] =>
[post_title] => Redacted Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:35:49
[post_modified_gmt] => 2020-08-06 06:35:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1232
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[71] => WP_Post Object
(
[ID] => 1231
[post_author] => 6
[post_date] => 2020-05-22 20:54:50
[post_date_gmt] => 2020-05-22 20:54:50
[post_content] =>
[post_title] => CAVD Data & Materials Sharing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cavd-data-materials-sharing-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:37:41
[post_modified_gmt] => 2020-08-06 06:37:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1231
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[72] => WP_Post Object
(
[ID] => 1229
[post_author] => 6
[post_date] => 2020-05-22 20:51:35
[post_date_gmt] => 2020-05-22 20:51:35
[post_content] =>
[post_title] => MPP License Agreement with BMS & Aurobindo Pharma Ltd.
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-bms-aurobindo-pharma-ltd-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:39:20
[post_modified_gmt] => 2020-08-06 06:39:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1229
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[73] => WP_Post Object
(
[ID] => 1228
[post_author] => 6
[post_date] => 2020-05-22 20:49:20
[post_date_gmt] => 2020-05-22 20:49:20
[post_content] =>
[post_title] => MPP License Agreement with Gilead
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-gilead-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:52:03
[post_modified_gmt] => 2020-08-06 19:52:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1228
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[74] => WP_Post Object
(
[ID] => 1227
[post_author] => 6
[post_date] => 2020-05-22 20:48:27
[post_date_gmt] => 2020-05-22 20:48:27
[post_content] =>
[post_title] => Ebola WHO-Manufacturer LOA (Annex)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ebola-who-manufacturer-loa-annex
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:52:47
[post_modified_gmt] => 2020-08-06 19:52:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1227
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[75] => WP_Post Object
(
[ID] => 1226
[post_author] => 6
[post_date] => 2020-05-22 20:47:05
[post_date_gmt] => 2020-05-22 20:47:05
[post_content] =>
[post_title] => WHO Template Material Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-template-material-transfer-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:44:21
[post_modified_gmt] => 2020-08-06 06:44:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1226
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[76] => WP_Post Object
(
[ID] => 1225
[post_author] => 6
[post_date] => 2020-05-22 20:43:20
[post_date_gmt] => 2020-05-22 20:43:20
[post_content] =>
[post_title] => WHO Template Material Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-template-material-transfer-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:45:39
[post_modified_gmt] => 2020-08-06 06:45:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1225
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[77] => WP_Post Object
(
[ID] => 1223
[post_author] => 6
[post_date] => 2020-05-22 20:14:40
[post_date_gmt] => 2020-05-22 20:14:40
[post_content] =>
[post_title] => Ten Principles for Socially Responsible Licensing, by Netherlands Federation of University Medical Centers (June 2019)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ten-principles-for-socially-responsible-licensing-by-netherlands-federation-of-university-medical-centers-june-2019-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:46:21
[post_modified_gmt] => 2020-08-06 06:46:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1223
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[78] => WP_Post Object
(
[ID] => 1222
[post_author] => 6
[post_date] => 2020-05-22 20:12:04
[post_date_gmt] => 2020-05-22 20:12:04
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfpi3-template-funding-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:47:07
[post_modified_gmt] => 2020-08-06 06:47:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1222
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[79] => WP_Post Object
(
[ID] => 1221
[post_author] => 6
[post_date] => 2020-05-22 20:09:53
[post_date_gmt] => 2020-05-22 20:09:53
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfpi3-template-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:55:03
[post_modified_gmt] => 2020-08-06 19:55:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1221
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[80] => WP_Post Object
(
[ID] => 1220
[post_author] => 6
[post_date] => 2020-05-22 20:05:59
[post_date_gmt] => 2020-05-22 20:05:59
[post_content] =>
[post_title] => Redacted Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:48:16
[post_modified_gmt] => 2020-08-06 06:48:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[81] => WP_Post Object
(
[ID] => 1218
[post_author] => 6
[post_date] => 2020-05-22 20:04:53
[post_date_gmt] => 2020-05-22 20:04:53
[post_content] =>
[post_title] => CARB-X Research Subaward Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => carb-x-research-subaward-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:57:30
[post_modified_gmt] => 2020-08-06 19:57:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1218
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[82] => WP_Post Object
(
[ID] => 1217
[post_author] => 6
[post_date] => 2020-05-22 20:00:26
[post_date_gmt] => 2020-05-22 20:00:26
[post_content] =>
[post_title] => EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => edctp2-policy-on-clinical-trials-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:16:02
[post_modified_gmt] => 2020-08-06 07:16:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1217
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[83] => WP_Post Object
(
[ID] => 1216
[post_author] => 6
[post_date] => 2020-05-22 19:58:08
[post_date_gmt] => 2020-05-22 19:58:08
[post_content] =>
[post_title] => EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => edctp2-policy-on-clinical-trials
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:54:51
[post_modified_gmt] => 2020-08-06 06:54:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1216
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[84] => WP_Post Object
(
[ID] => 1215
[post_author] => 6
[post_date] => 2020-05-22 19:56:47
[post_date_gmt] => 2020-05-22 19:56:47
[post_content] =>
[post_title] => EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => edctp2-policy-on-clinical-trials-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:56:31
[post_modified_gmt] => 2020-08-06 06:56:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1215
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[85] => WP_Post Object
(
[ID] => 1214
[post_author] => 6
[post_date] => 2020-05-22 19:55:41
[post_date_gmt] => 2020-05-22 19:55:41
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-14
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:57:53
[post_modified_gmt] => 2020-08-06 06:57:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1214
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[86] => WP_Post Object
(
[ID] => 1211
[post_author] => 6
[post_date] => 2020-05-22 19:50:22
[post_date_gmt] => 2020-05-22 19:50:22
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:58:52
[post_modified_gmt] => 2020-08-06 06:58:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1211
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[87] => WP_Post Object
(
[ID] => 1210
[post_author] => 6
[post_date] => 2020-05-22 19:49:19
[post_date_gmt] => 2020-05-22 19:49:19
[post_content] =>
[post_title] => Ten Principles for Socially Responsible Licensing, by Netherlands Federation of University Medical Centers (June 2019)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ten-principles-for-socially-responsible-licensing-by-netherlands-federation-of-university-medical-centers-june-2019
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:59:22
[post_modified_gmt] => 2020-08-06 06:59:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1210
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[88] => WP_Post Object
(
[ID] => 1207
[post_author] => 6
[post_date] => 2020-05-22 19:42:36
[post_date_gmt] => 2020-05-22 19:42:36
[post_content] =>
[post_title] => MPP License Agreement with Pfizer re Sutezolid
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-pfizer-re-sutezolid
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:59:52
[post_modified_gmt] => 2020-08-06 06:59:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1207
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[89] => WP_Post Object
(
[ID] => 1206
[post_author] => 6
[post_date] => 2020-05-22 19:37:27
[post_date_gmt] => 2020-05-22 19:37:27
[post_content] =>
[post_title] => Gates Global Access Commitment & Humanitarian License
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-global-access-commitment-and-humanitarian-license
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:00:51
[post_modified_gmt] => 2020-08-06 07:00:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1206
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[90] => WP_Post Object
(
[ID] => 1200
[post_author] => 6
[post_date] => 2020-05-22 19:35:05
[post_date_gmt] => 2020-05-22 19:35:05
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 20:02:26
[post_modified_gmt] => 2020-08-06 20:02:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1200
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[91] => WP_Post Object
(
[ID] => 1205
[post_author] => 6
[post_date] => 2020-05-22 19:33:17
[post_date_gmt] => 2020-05-22 19:33:17
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:04:45
[post_modified_gmt] => 2020-08-06 07:04:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1205
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[92] => WP_Post Object
(
[ID] => 1204
[post_author] => 6
[post_date] => 2020-05-22 19:31:46
[post_date_gmt] => 2020-05-22 19:31:46
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:06:42
[post_modified_gmt] => 2020-08-06 07:06:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1204
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[93] => WP_Post Object
(
[ID] => 1203
[post_author] => 6
[post_date] => 2020-05-22 19:30:52
[post_date_gmt] => 2020-05-22 19:30:52
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:07:29
[post_modified_gmt] => 2020-08-06 07:07:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1203
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[94] => WP_Post Object
(
[ID] => 1202
[post_author] => 6
[post_date] => 2020-05-22 19:28:49
[post_date_gmt] => 2020-05-22 19:28:49
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-09-06 23:38:12
[post_modified_gmt] => 2020-09-06 23:38:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1202
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[95] => WP_Post Object
(
[ID] => 1201
[post_author] => 6
[post_date] => 2020-05-22 19:26:29
[post_date_gmt] => 2020-05-22 19:26:29
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:09:26
[post_modified_gmt] => 2020-08-06 07:09:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1201
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[96] => WP_Post Object
(
[ID] => 1199
[post_author] => 6
[post_date] => 2020-05-22 19:21:57
[post_date_gmt] => 2020-05-22 19:21:57
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:11:10
[post_modified_gmt] => 2020-08-06 07:11:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1199
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[97] => WP_Post Object
(
[ID] => 1198
[post_author] => 6
[post_date] => 2020-05-22 19:12:54
[post_date_gmt] => 2020-05-22 19:12:54
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:12:41
[post_modified_gmt] => 2020-08-06 07:12:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1198
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[98] => WP_Post Object
(
[ID] => 1193
[post_author] => 6
[post_date] => 2020-05-22 02:10:10
[post_date_gmt] => 2020-05-22 02:10:10
[post_content] =>
[post_title] => Aridis-PATH Vaccine Formulation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-04 04:18:05
[post_modified_gmt] => 2020-08-04 04:18:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1193
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[99] => WP_Post Object
(
[ID] => 1190
[post_author] => 6
[post_date] => 2020-05-22 01:59:48
[post_date_gmt] => 2020-05-22 01:59:48
[post_content] =>
[post_title] => Aridis-PATH Vaccine Formulation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:13:53
[post_modified_gmt] => 2020-08-06 07:13:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1190
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[100] => WP_Post Object
(
[ID] => 1187
[post_author] => 6
[post_date] => 2020-05-22 01:56:10
[post_date_gmt] => 2020-05-22 01:56:10
[post_content] =>
[post_title] => CARB-X Research Subaward Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => carb-x-research-subaward-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:15:18
[post_modified_gmt] => 2020-08-06 07:15:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1187
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[101] => WP_Post Object
(
[ID] => 1186
[post_author] => 6
[post_date] => 2020-05-22 00:11:20
[post_date_gmt] => 2020-05-22 00:11:20
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-iia-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:19:26
[post_modified_gmt] => 2020-08-06 07:19:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1186
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[102] => WP_Post Object
(
[ID] => 1185
[post_author] => 6
[post_date] => 2020-05-22 00:10:01
[post_date_gmt] => 2020-05-22 00:10:01
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:19:08
[post_modified_gmt] => 2020-08-06 07:19:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1185
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[103] => WP_Post Object
(
[ID] => 1184
[post_author] => 6
[post_date] => 2020-05-22 00:08:17
[post_date_gmt] => 2020-05-22 00:08:17
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:18:30
[post_modified_gmt] => 2020-08-06 07:18:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1184
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[104] => WP_Post Object
(
[ID] => 1183
[post_author] => 6
[post_date] => 2020-05-22 00:06:26
[post_date_gmt] => 2020-05-22 00:06:26
[post_content] =>
[post_title] => MPP License Agreement with AbbVie (LPV r)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-abbvie
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:20:18
[post_modified_gmt] => 2020-08-06 07:20:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1183
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[105] => WP_Post Object
(
[ID] => 1182
[post_author] => 6
[post_date] => 2020-05-22 00:02:42
[post_date_gmt] => 2020-05-22 00:02:42
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-iia-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 20:22:28
[post_modified_gmt] => 2020-08-06 20:22:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1182
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[106] => WP_Post Object
(
[ID] => 1179
[post_author] => 6
[post_date] => 2020-05-21 23:58:21
[post_date_gmt] => 2020-05-21 23:58:21
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 20:23:03
[post_modified_gmt] => 2020-08-06 20:23:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1179
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[107] => WP_Post Object
(
[ID] => 1178
[post_author] => 6
[post_date] => 2020-05-21 23:55:50
[post_date_gmt] => 2020-05-21 23:55:50
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:23:22
[post_modified_gmt] => 2020-08-06 07:23:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1178
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[108] => WP_Post Object
(
[ID] => 1177
[post_author] => 6
[post_date] => 2020-05-21 23:53:56
[post_date_gmt] => 2020-05-21 23:53:56
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:24:45
[post_modified_gmt] => 2020-08-06 07:24:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1177
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[109] => WP_Post Object
(
[ID] => 1176
[post_author] => 6
[post_date] => 2020-05-21 23:52:12
[post_date_gmt] => 2020-05-21 23:52:12
[post_content] =>
[post_title] => Aridis-PATH Vaccine Formulation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:26:01
[post_modified_gmt] => 2020-08-06 07:26:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1176
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[110] => WP_Post Object
(
[ID] => 1175
[post_author] => 6
[post_date] => 2020-05-21 23:44:57
[post_date_gmt] => 2020-05-21 23:44:57
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:28:09
[post_modified_gmt] => 2020-08-06 07:28:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1175
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[111] => WP_Post Object
(
[ID] => 1173
[post_author] => 6
[post_date] => 2020-05-21 23:37:42
[post_date_gmt] => 2020-05-21 23:37:42
[post_content] =>
[post_title] => CARB-X Research Subaward Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => carb-x-research-subaward-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 20:28:01
[post_modified_gmt] => 2020-08-06 20:28:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1173
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[112] => WP_Post Object
(
[ID] => 1172
[post_author] => 6
[post_date] => 2020-05-21 23:35:57
[post_date_gmt] => 2020-05-21 23:35:57
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:48:07
[post_modified_gmt] => 2020-08-06 07:48:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1172
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[113] => WP_Post Object
(
[ID] => 1171
[post_author] => 6
[post_date] => 2020-05-21 23:33:24
[post_date_gmt] => 2020-05-21 23:33:24
[post_content] =>
[post_title] => IMI 1 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-1-model-grant-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:34:16
[post_modified_gmt] => 2020-08-06 07:34:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1171
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[114] => WP_Post Object
(
[ID] => 1170
[post_author] => 6
[post_date] => 2020-05-21 23:28:59
[post_date_gmt] => 2020-05-21 23:28:59
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:46:46
[post_modified_gmt] => 2020-08-06 07:46:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1170
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[115] => WP_Post Object
(
[ID] => 1168
[post_author] => 6
[post_date] => 2020-05-21 23:26:48
[post_date_gmt] => 2020-05-21 23:26:48
[post_content] =>
[post_title] => NIH Model License Agreement for Use by Non-Profit
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-model-license-agreement-for-use-by-non-profit-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:45:59
[post_modified_gmt] => 2020-08-06 07:45:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1168
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[116] => WP_Post Object
(
[ID] => 1166
[post_author] => 6
[post_date] => 2020-05-21 23:26:07
[post_date_gmt] => 2020-05-21 23:26:07
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:45:40
[post_modified_gmt] => 2020-08-06 07:45:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1166
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[117] => WP_Post Object
(
[ID] => 1165
[post_author] => 6
[post_date] => 2020-05-21 23:23:57
[post_date_gmt] => 2020-05-21 23:23:57
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:44:57
[post_modified_gmt] => 2020-08-06 07:44:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1165
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[118] => WP_Post Object
(
[ID] => 1164
[post_author] => 6
[post_date] => 2020-05-21 23:22:37
[post_date_gmt] => 2020-05-21 23:22:37
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-iia
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 20:30:07
[post_modified_gmt] => 2020-08-06 20:30:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1164
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[119] => WP_Post Object
(
[ID] => 1162
[post_author] => 6
[post_date] => 2020-05-21 23:19:43
[post_date_gmt] => 2020-05-21 23:19:43
[post_content] =>
[post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:43:25
[post_modified_gmt] => 2020-08-06 07:43:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1162
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[120] => WP_Post Object
(
[ID] => 1160
[post_author] => 6
[post_date] => 2020-05-21 23:18:03
[post_date_gmt] => 2020-05-21 23:18:03
[post_content] =>
[post_title] => Aridis-PATH Vaccine Formulation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:41:09
[post_modified_gmt] => 2020-08-06 07:41:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1160
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[121] => WP_Post Object
(
[ID] => 1159
[post_author] => 6
[post_date] => 2020-05-21 23:14:15
[post_date_gmt] => 2020-05-21 23:14:15
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:39:58
[post_modified_gmt] => 2020-08-06 07:39:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1159
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[122] => WP_Post Object
(
[ID] => 1158
[post_author] => 6
[post_date] => 2020-05-21 23:12:13
[post_date_gmt] => 2020-05-21 23:12:13
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:38:32
[post_modified_gmt] => 2020-08-06 07:38:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1158
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[123] => WP_Post Object
(
[ID] => 1156
[post_author] => 6
[post_date] => 2020-05-21 23:10:39
[post_date_gmt] => 2020-05-21 23:10:39
[post_content] =>
[post_title] => WHO Standard Framework Memorandum of Understanding
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-standard-framework-memorandum-of-understanding
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:36:26
[post_modified_gmt] => 2020-08-06 07:36:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1156
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[124] => WP_Post Object
(
[ID] => 1155
[post_author] => 6
[post_date] => 2020-05-21 23:09:39
[post_date_gmt] => 2020-05-21 23:09:39
[post_content] =>
[post_title] => WHO Template Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => template-collaboration-agreement-with-who
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:13:07
[post_modified_gmt] => 2020-08-06 08:13:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1155
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[125] => WP_Post Object
(
[ID] => 1150
[post_author] => 6
[post_date] => 2020-05-21 22:53:25
[post_date_gmt] => 2020-05-21 22:53:25
[post_content] =>
[post_title] => Redacted Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:15:03
[post_modified_gmt] => 2020-08-06 08:15:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1150
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[126] => WP_Post Object
(
[ID] => 1147
[post_author] => 6
[post_date] => 2020-05-21 22:50:33
[post_date_gmt] => 2020-05-21 22:50:33
[post_content] =>
[post_title] => IMI 1 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-1-model-grant-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:15:52
[post_modified_gmt] => 2020-08-06 08:15:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1147
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[127] => WP_Post Object
(
[ID] => 1145
[post_author] => 6
[post_date] => 2020-05-21 22:48:08
[post_date_gmt] => 2020-05-21 22:48:08
[post_content] =>
[post_title] => Gilead HCV License Agreement with Indian Generic Manufacturers
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:17:09
[post_modified_gmt] => 2020-08-06 08:17:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1145
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[128] => WP_Post Object
(
[ID] => 1143
[post_author] => 6
[post_date] => 2020-05-21 22:46:30
[post_date_gmt] => 2020-05-21 22:46:30
[post_content] =>
[post_title] => MPP License Agreement with Gilead
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-gilead-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:18:12
[post_modified_gmt] => 2020-08-06 08:18:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1143
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[129] => WP_Post Object
(
[ID] => 1141
[post_author] => 6
[post_date] => 2020-05-21 22:43:46
[post_date_gmt] => 2020-05-21 22:43:46
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:19:21
[post_modified_gmt] => 2020-08-06 08:19:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1141
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[130] => WP_Post Object
(
[ID] => 1140
[post_author] => 6
[post_date] => 2020-05-21 22:37:27
[post_date_gmt] => 2020-05-21 22:37:27
[post_content] =>
[post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:21:40
[post_modified_gmt] => 2020-08-06 08:21:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1140
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[131] => WP_Post Object
(
[ID] => 1139
[post_author] => 6
[post_date] => 2020-05-21 22:35:04
[post_date_gmt] => 2020-05-21 22:35:04
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:22:26
[post_modified_gmt] => 2020-08-06 08:22:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1139
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[132] => WP_Post Object
(
[ID] => 1137
[post_author] => 6
[post_date] => 2020-05-21 22:22:50
[post_date_gmt] => 2020-05-21 22:22:50
[post_content] =>
[post_title] => Gilead HCV License Agreement with Indian Generic Manufacturers
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:25:03
[post_modified_gmt] => 2020-08-06 08:25:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1137
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[133] => WP_Post Object
(
[ID] => 1135
[post_author] => 6
[post_date] => 2020-05-21 22:19:46
[post_date_gmt] => 2020-05-21 22:19:46
[post_content] =>
[post_title] => NIH Model License Agreement for Use by Non-Profit
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-model-license-agreement-for-use-by-non-profit
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:25:31
[post_modified_gmt] => 2020-08-06 08:25:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1135
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[134] => WP_Post Object
(
[ID] => 1134
[post_author] => 6
[post_date] => 2020-05-21 22:00:36
[post_date_gmt] => 2020-05-21 22:00:36
[post_content] =>
[post_title] => CAVD Data & Materials Sharing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cavd-data-materials-sharing-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:25:48
[post_modified_gmt] => 2020-08-06 08:25:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1134
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[135] => WP_Post Object
(
[ID] => 1132
[post_author] => 6
[post_date] => 2020-05-21 21:58:10
[post_date_gmt] => 2020-05-21 21:58:10
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:27:59
[post_modified_gmt] => 2020-08-06 08:27:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1132
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[136] => WP_Post Object
(
[ID] => 1131
[post_author] => 6
[post_date] => 2020-05-21 21:56:27
[post_date_gmt] => 2020-05-21 21:56:27
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-%c2%a725-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:12:00
[post_modified_gmt] => 2020-08-06 08:12:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1131
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[137] => WP_Post Object
(
[ID] => 1129
[post_author] => 6
[post_date] => 2020-05-21 21:51:51
[post_date_gmt] => 2020-05-21 21:51:51
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement §25.2
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:10:01
[post_modified_gmt] => 2020-08-06 08:10:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1129
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[138] => WP_Post Object
(
[ID] => 1128
[post_author] => 6
[post_date] => 2020-05-21 21:50:04
[post_date_gmt] => 2020-05-21 21:50:04
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:09:28
[post_modified_gmt] => 2020-08-06 08:09:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1128
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[139] => WP_Post Object
(
[ID] => 1127
[post_author] => 6
[post_date] => 2020-05-21 21:47:49
[post_date_gmt] => 2020-05-21 21:47:49
[post_content] =>
[post_title] => BU Startup Exclusive License
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bu-startup-exclusive-license
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:08:46
[post_modified_gmt] => 2020-08-06 08:08:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1127
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[140] => WP_Post Object
(
[ID] => 1125
[post_author] => 6
[post_date] => 2020-05-21 21:44:59
[post_date_gmt] => 2020-05-21 21:44:59
[post_content] =>
[post_title] => MPP Sublicense Agreement under AbbVie-MPP License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:08:05
[post_modified_gmt] => 2020-08-06 08:08:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1125
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[141] => WP_Post Object
(
[ID] => 1124
[post_author] => 6
[post_date] => 2020-05-21 21:41:21
[post_date_gmt] => 2020-05-21 21:41:21
[post_content] =>
[post_title] => MPP Amended and Restated Sublicense and Technology Transfer Agreement under BMS-MPP License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:06:09
[post_modified_gmt] => 2020-08-06 08:06:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1124
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[142] => WP_Post Object
(
[ID] => 1123
[post_author] => 6
[post_date] => 2020-05-21 21:37:52
[post_date_gmt] => 2020-05-21 21:37:52
[post_content] =>
[post_title] => MPP License Agreement with ViiV on Dolutegravir for Adults
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-viiv-on-dolutegravir-for-adults
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:02:41
[post_modified_gmt] => 2020-08-06 08:02:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1123
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[143] => WP_Post Object
(
[ID] => 1122
[post_author] => 6
[post_date] => 2020-05-21 21:30:19
[post_date_gmt] => 2020-05-21 21:30:19
[post_content] =>
[post_title] => MPP License Agreement with BMS & Aurobindo Pharma Ltd.
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-bms-aurobindo-pharma-ltd
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:02:05
[post_modified_gmt] => 2020-08-06 08:02:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1122
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[144] => WP_Post Object
(
[ID] => 1120
[post_author] => 6
[post_date] => 2020-05-21 21:28:37
[post_date_gmt] => 2020-05-21 21:28:37
[post_content] =>
[post_title] => MPP Sublicense Agreement under AbbVie-MPP License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-sublicense-agreement-under-abbvie-mpp-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:00:43
[post_modified_gmt] => 2020-08-06 08:00:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1120
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[145] => WP_Post Object
(
[ID] => 1118
[post_author] => 6
[post_date] => 2020-05-21 21:24:00
[post_date_gmt] => 2020-05-21 21:24:00
[post_content] =>
[post_title] => MPP License Agreement with AbbVie (LPV r)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpps-license-agreement-with-abbvie
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:59:29
[post_modified_gmt] => 2020-08-06 07:59:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1118
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[146] => WP_Post Object
(
[ID] => 1117
[post_author] => 6
[post_date] => 2020-05-21 21:17:31
[post_date_gmt] => 2020-05-21 21:17:31
[post_content] =>
[post_title] => MPP License Agreement with University of Liverpool
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpps-license-agreement-with-university-of-liverpool
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:58:09
[post_modified_gmt] => 2020-08-06 07:58:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1117
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[147] => WP_Post Object
(
[ID] => 1114
[post_author] => 6
[post_date] => 2020-05-21 21:13:15
[post_date_gmt] => 2020-05-21 21:13:15
[post_content] =>
[post_title] => MPP License Agreement with Gilead
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-gilead
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:55:36
[post_modified_gmt] => 2020-08-06 07:55:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1114
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[148] => WP_Post Object
(
[ID] => 1113
[post_author] => 6
[post_date] => 2020-05-21 21:09:47
[post_date_gmt] => 2020-05-21 21:09:47
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-15
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:54:21
[post_modified_gmt] => 2020-08-06 07:54:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1113
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[149] => WP_Post Object
(
[ID] => 1112
[post_author] => 6
[post_date] => 2020-05-21 21:06:05
[post_date_gmt] => 2020-05-21 21:06:05
[post_content] =>
[post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:53:41
[post_modified_gmt] => 2020-08-06 07:53:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1112
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[150] => WP_Post Object
(
[ID] => 1111
[post_author] => 6
[post_date] => 2020-05-21 21:03:23
[post_date_gmt] => 2020-05-21 21:03:23
[post_content] =>
[post_title] => IMI 1 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-1-model-grant-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:53:03
[post_modified_gmt] => 2020-08-06 07:53:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1111
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[151] => WP_Post Object
(
[ID] => 1109
[post_author] => 6
[post_date] => 2020-05-21 21:01:18
[post_date_gmt] => 2020-05-21 21:01:18
[post_content] =>
[post_title] => CAVD Data & Materials Sharing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cavd-data-materials-sharing-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-04 04:28:44
[post_modified_gmt] => 2020-08-04 04:28:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1109
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[152] => WP_Post Object
(
[ID] => 1108
[post_author] => 6
[post_date] => 2020-05-21 20:59:47
[post_date_gmt] => 2020-05-21 20:59:47
[post_content] =>
[post_title] => WHO Template Material Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-template-material-transfer-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:51:26
[post_modified_gmt] => 2020-08-06 07:51:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1108
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[153] => WP_Post Object
(
[ID] => 1107
[post_author] => 6
[post_date] => 2020-05-21 20:57:25
[post_date_gmt] => 2020-05-21 20:57:25
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:50:28
[post_modified_gmt] => 2020-08-06 07:50:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1107
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[154] => WP_Post Object
(
[ID] => 996
[post_author] => 7
[post_date] => 2020-05-18 19:58:18
[post_date_gmt] => 2020-05-18 19:58:18
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:49:31
[post_modified_gmt] => 2020-08-06 07:49:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=996
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 155
[current_post] => -1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 2425
[post_author] => 5
[post_date] => 2020-12-14 15:02:33
[post_date_gmt] => 2020-12-14 15:02:33
[post_content] =>
[post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-12-22 10:41:23
[post_modified_gmt] => 2020-12-22 10:41:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2425
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 155
[max_num_pages] => 0
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] => 1
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] =>
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] => 1
[query_vars_hash:WP_Query:private] => 1c3df41be9f14460b814a5bb3f65f565
[query_vars_changed:WP_Query:private] => 1
[thumbnails_cached] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
[text_agreement_q_rslts] =>
[text_provision_q_rslts] =>
[provisions] => Array
(
[0] => WP_Post Object
(
[ID] => 2425
[post_author] => 5
[post_date] => 2020-12-14 15:02:33
[post_date_gmt] => 2020-12-14 15:02:33
[post_content] =>
[post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-12-22 10:41:23
[post_modified_gmt] => 2020-12-22 10:41:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2425
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 2426
[post_author] => 5
[post_date] => 2020-12-14 15:02:08
[post_date_gmt] => 2020-12-14 15:02:08
[post_content] =>
[post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-12-22 13:52:16
[post_modified_gmt] => 2020-12-22 13:52:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2426
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 2424
[post_author] => 5
[post_date] => 2020-12-14 15:01:40
[post_date_gmt] => 2020-12-14 15:01:40
[post_content] =>
[post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-12-22 13:51:02
[post_modified_gmt] => 2020-12-22 13:51:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2424
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 2422
[post_author] => 5
[post_date] => 2020-12-14 14:59:29
[post_date_gmt] => 2020-12-14 14:59:29
[post_content] =>
[post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended
[to_ping] =>
[pinged] =>
[post_modified] => 2020-12-22 10:43:20
[post_modified_gmt] => 2020-12-22 10:43:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2422
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 1395
[post_author] => 7
[post_date] => 2020-05-30 21:25:33
[post_date_gmt] => 2020-05-30 21:25:33
[post_content] =>
[post_title] => Gates Foundation Sample Terms & Conditions for Project Support Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-sample-terms-conditions-for-project-support-grant-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:28:33
[post_modified_gmt] => 2020-08-06 08:28:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1395
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 1394
[post_author] => 7
[post_date] => 2020-05-30 21:22:44
[post_date_gmt] => 2020-05-30 21:22:44
[post_content] =>
[post_title] => Gates Foundation Sample Terms & Conditions for Project Support Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-sample-terms-conditions-for-project-support-grant-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:40:24
[post_modified_gmt] => 2020-08-06 05:40:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1394
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 1393
[post_author] => 7
[post_date] => 2020-05-30 20:13:50
[post_date_gmt] => 2020-05-30 20:13:50
[post_content] =>
[post_title] => Gates Foundation Open Access Policy
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 1393
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 04:49:54
[post_modified_gmt] => 2020-08-06 04:49:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1393
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 1315
[post_author] => 7
[post_date] => 2020-05-23 17:56:03
[post_date_gmt] => 2020-05-23 17:56:03
[post_content] =>
[post_title] => MPP License Agreement with ViiV on Dolutegravir for Adults
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-viiv-on-dolutegravir-for-adults-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-10-10 22:05:56
[post_modified_gmt] => 2020-10-10 22:05:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1315
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 1313
[post_author] => 7
[post_date] => 2020-05-23 17:55:00
[post_date_gmt] => 2020-05-23 17:55:00
[post_content] =>
[post_title] => MPP Sublicense Agreement under AbbVie-MPP License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-04 05:11:03
[post_modified_gmt] => 2020-08-04 05:11:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1313
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 1314
[post_author] => 7
[post_date] => 2020-05-23 17:54:57
[post_date_gmt] => 2020-05-23 17:54:57
[post_content] =>
[post_title] => MPP Amended and Restated Sublicense and Technology Transfer Agreement under BMS-MPP License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-10-10 22:08:33
[post_modified_gmt] => 2020-10-10 22:08:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1314
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 1308
[post_author] => 7
[post_date] => 2020-05-23 17:17:48
[post_date_gmt] => 2020-05-23 17:17:48
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 04:59:05
[post_modified_gmt] => 2020-08-06 04:59:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1308
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 1309
[post_author] => 7
[post_date] => 2020-05-23 17:17:44
[post_date_gmt] => 2020-05-23 17:17:44
[post_content] =>
[post_title] => IMI 2Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2joint-undertaking-model-consortium-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 04:59:37
[post_modified_gmt] => 2020-08-06 04:59:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1309
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 1311
[post_author] => 7
[post_date] => 2020-05-23 17:12:09
[post_date_gmt] => 2020-05-23 17:12:09
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:43:06
[post_modified_gmt] => 2020-08-06 05:43:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1311
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 1310
[post_author] => 7
[post_date] => 2020-05-23 17:12:02
[post_date_gmt] => 2020-05-23 17:12:02
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:30:05
[post_modified_gmt] => 2020-08-06 08:30:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1310
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 1307
[post_author] => 7
[post_date] => 2020-05-23 17:05:21
[post_date_gmt] => 2020-05-23 17:05:21
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2020-10-10 22:20:30
[post_modified_gmt] => 2020-10-10 22:20:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1307
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 1306
[post_author] => 7
[post_date] => 2020-05-23 16:57:14
[post_date_gmt] => 2020-05-23 16:57:14
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:45:45
[post_modified_gmt] => 2020-08-06 05:45:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1306
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 1305
[post_author] => 7
[post_date] => 2020-05-23 16:51:40
[post_date_gmt] => 2020-05-23 16:51:40
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 1305
[to_ping] =>
[pinged] =>
[post_modified] => 2020-10-10 22:21:50
[post_modified_gmt] => 2020-10-10 22:21:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1305
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 1304
[post_author] => 7
[post_date] => 2020-05-23 16:46:37
[post_date_gmt] => 2020-05-23 16:46:37
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:47:49
[post_modified_gmt] => 2020-08-06 05:47:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1304
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 1303
[post_author] => 7
[post_date] => 2020-05-23 16:46:30
[post_date_gmt] => 2020-05-23 16:46:30
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:48:31
[post_modified_gmt] => 2020-08-06 05:48:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1303
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 1296
[post_author] => 6
[post_date] => 2020-05-22 23:46:47
[post_date_gmt] => 2020-05-22 23:46:47
[post_content] =>
[post_title] => WHO
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:49:42
[post_modified_gmt] => 2020-08-06 05:49:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1296
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 1291
[post_author] => 6
[post_date] => 2020-05-22 23:42:19
[post_date_gmt] => 2020-05-22 23:42:19
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm
[to_ping] =>
[pinged] =>
[post_modified] => 2020-10-10 22:25:11
[post_modified_gmt] => 2020-10-10 22:25:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1291
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 1293
[post_author] => 6
[post_date] => 2020-05-22 23:42:02
[post_date_gmt] => 2020-05-22 23:42:02
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-13
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:50:33
[post_modified_gmt] => 2020-08-06 05:50:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1293
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 1288
[post_author] => 6
[post_date] => 2020-05-22 23:31:30
[post_date_gmt] => 2020-05-22 23:31:30
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:15:24
[post_modified_gmt] => 2020-08-06 19:15:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1288
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 1287
[post_author] => 6
[post_date] => 2020-05-22 23:05:30
[post_date_gmt] => 2020-05-22 23:05:30
[post_content] =>
[post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation).
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-10
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-07 14:11:07
[post_modified_gmt] => 2020-08-07 14:11:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1287
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[24] => WP_Post Object
(
[ID] => 1285
[post_author] => 6
[post_date] => 2020-05-22 23:01:07
[post_date_gmt] => 2020-05-22 23:01:07
[post_content] =>
[post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation).
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:55:08
[post_modified_gmt] => 2020-08-06 05:55:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1285
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[25] => WP_Post Object
(
[ID] => 1284
[post_author] => 6
[post_date] => 2020-05-22 22:58:55
[post_date_gmt] => 2020-05-22 22:58:55
[post_content] =>
[post_title] => Aridis-PATH Vaccine Formulation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:55:57
[post_modified_gmt] => 2020-08-06 05:55:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1284
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[26] => WP_Post Object
(
[ID] => 1283
[post_author] => 6
[post_date] => 2020-05-22 22:57:44
[post_date_gmt] => 2020-05-22 22:57:44
[post_content] =>
[post_title] => Aridis-PATH Vaccine Formulation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:56:15
[post_modified_gmt] => 2020-08-06 05:56:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1283
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[27] => WP_Post Object
(
[ID] => 1282
[post_author] => 6
[post_date] => 2020-05-22 22:56:18
[post_date_gmt] => 2020-05-22 22:56:18
[post_content] =>
[post_title] => Redacted Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:56:57
[post_modified_gmt] => 2020-08-06 05:56:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1282
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[28] => WP_Post Object
(
[ID] => 1281
[post_author] => 6
[post_date] => 2020-05-22 22:55:22
[post_date_gmt] => 2020-05-22 22:55:22
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-12
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:57:24
[post_modified_gmt] => 2020-08-06 05:57:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1281
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[29] => WP_Post Object
(
[ID] => 1280
[post_author] => 6
[post_date] => 2020-05-22 22:54:32
[post_date_gmt] => 2020-05-22 22:54:32
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-iia-7
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:57:59
[post_modified_gmt] => 2020-08-06 05:57:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1280
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[30] => WP_Post Object
(
[ID] => 1276
[post_author] => 6
[post_date] => 2020-05-22 22:40:34
[post_date_gmt] => 2020-05-22 22:40:34
[post_content] =>
[post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-8
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:58:18
[post_modified_gmt] => 2020-08-06 05:58:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1276
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[31] => WP_Post Object
(
[ID] => 1275
[post_author] => 6
[post_date] => 2020-05-22 22:39:41
[post_date_gmt] => 2020-05-22 22:39:41
[post_content] =>
[post_title] => Aridis-PATH Vaccine Formulation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:58:40
[post_modified_gmt] => 2020-08-06 05:58:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1275
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[32] => WP_Post Object
(
[ID] => 1274
[post_author] => 6
[post_date] => 2020-05-22 22:38:47
[post_date_gmt] => 2020-05-22 22:38:47
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:59:08
[post_modified_gmt] => 2020-08-06 05:59:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1274
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[33] => WP_Post Object
(
[ID] => 1273
[post_author] => 6
[post_date] => 2020-05-22 22:37:54
[post_date_gmt] => 2020-05-22 22:37:54
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-iia-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-04 04:20:47
[post_modified_gmt] => 2020-08-04 04:20:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1273
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[34] => WP_Post Object
(
[ID] => 1272
[post_author] => 6
[post_date] => 2020-05-22 22:36:39
[post_date_gmt] => 2020-05-22 22:36:39
[post_content] =>
[post_title] => BU Startup Exclusive License
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bu-startup-exclusive-license-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 05:59:41
[post_modified_gmt] => 2020-08-06 05:59:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1272
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[35] => WP_Post Object
(
[ID] => 1271
[post_author] => 6
[post_date] => 2020-05-22 22:34:12
[post_date_gmt] => 2020-05-22 22:34:12
[post_content] =>
[post_title] => WHO Standard Framework Memorandum of Understanding
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-standard-framework-memorandum-of-understanding-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:00:10
[post_modified_gmt] => 2020-08-06 06:00:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1271
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[36] => WP_Post Object
(
[ID] => 1270
[post_author] => 6
[post_date] => 2020-05-22 22:32:29
[post_date_gmt] => 2020-05-22 22:32:29
[post_content] =>
[post_title] => MPP License Agreement with Gilead
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-gilead-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-10-18 11:46:22
[post_modified_gmt] => 2020-10-18 11:46:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1270
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[37] => WP_Post Object
(
[ID] => 1269
[post_author] => 6
[post_date] => 2020-05-22 22:29:54
[post_date_gmt] => 2020-05-22 22:29:54
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-11
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:01:05
[post_modified_gmt] => 2020-08-06 06:01:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1269
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[38] => WP_Post Object
(
[ID] => 1268
[post_author] => 6
[post_date] => 2020-05-22 22:27:54
[post_date_gmt] => 2020-05-22 22:27:54
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:01:30
[post_modified_gmt] => 2020-08-06 06:01:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1268
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[39] => WP_Post Object
(
[ID] => 1267
[post_author] => 6
[post_date] => 2020-05-22 22:26:39
[post_date_gmt] => 2020-05-22 22:26:39
[post_content] =>
[post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-7
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:02:22
[post_modified_gmt] => 2020-08-06 06:02:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1267
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[40] => WP_Post Object
(
[ID] => 1266
[post_author] => 6
[post_date] => 2020-05-22 22:25:16
[post_date_gmt] => 2020-05-22 22:25:16
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:03:25
[post_modified_gmt] => 2020-08-06 06:03:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1266
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[41] => WP_Post Object
(
[ID] => 1265
[post_author] => 6
[post_date] => 2020-05-22 22:24:11
[post_date_gmt] => 2020-05-22 22:24:11
[post_content] =>
[post_title] => WHO Template Material Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-template-material-transfer-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:03:50
[post_modified_gmt] => 2020-08-06 06:03:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1265
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[42] => WP_Post Object
(
[ID] => 1264
[post_author] => 6
[post_date] => 2020-05-22 22:22:55
[post_date_gmt] => 2020-05-22 22:22:55
[post_content] =>
[post_title] => Gilead HCV License Agreement with Indian Generic Manufacturers
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:04:26
[post_modified_gmt] => 2020-08-06 06:04:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1264
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[43] => WP_Post Object
(
[ID] => 1263
[post_author] => 6
[post_date] => 2020-05-22 22:20:56
[post_date_gmt] => 2020-05-22 22:20:56
[post_content] =>
[post_title] => MPP License Agreement with Gilead
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-gilead-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:21:52
[post_modified_gmt] => 2020-08-06 19:21:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1263
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[44] => WP_Post Object
(
[ID] => 1262
[post_author] => 6
[post_date] => 2020-05-22 22:18:41
[post_date_gmt] => 2020-05-22 22:18:41
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-10
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:05:46
[post_modified_gmt] => 2020-08-06 06:05:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1262
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[45] => WP_Post Object
(
[ID] => 1261
[post_author] => 6
[post_date] => 2020-05-22 22:17:34
[post_date_gmt] => 2020-05-22 22:17:34
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:06:36
[post_modified_gmt] => 2020-08-06 06:06:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1261
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[46] => WP_Post Object
(
[ID] => 1259
[post_author] => 6
[post_date] => 2020-05-22 22:04:31
[post_date_gmt] => 2020-05-22 22:04:31
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-9
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:06:50
[post_modified_gmt] => 2020-08-06 06:06:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1259
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[47] => WP_Post Object
(
[ID] => 1258
[post_author] => 6
[post_date] => 2020-05-22 22:03:08
[post_date_gmt] => 2020-05-22 22:03:08
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-8
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:07:40
[post_modified_gmt] => 2020-08-06 06:07:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1258
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[48] => WP_Post Object
(
[ID] => 1257
[post_author] => 6
[post_date] => 2020-05-22 21:54:08
[post_date_gmt] => 2020-05-22 21:54:08
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:08:19
[post_modified_gmt] => 2020-08-06 06:08:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1257
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[49] => WP_Post Object
(
[ID] => 1255
[post_author] => 6
[post_date] => 2020-05-22 21:49:26
[post_date_gmt] => 2020-05-22 21:49:26
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-7
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:09:08
[post_modified_gmt] => 2020-08-06 06:09:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1255
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[50] => WP_Post Object
(
[ID] => 1254
[post_author] => 6
[post_date] => 2020-05-22 21:44:49
[post_date_gmt] => 2020-05-22 21:44:49
[post_content] =>
[post_title] => Gates Foundation Data & Materials Sharing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-data-materials-sharing-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:09:56
[post_modified_gmt] => 2020-08-06 06:09:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1254
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[51] => WP_Post Object
(
[ID] => 1253
[post_author] => 6
[post_date] => 2020-05-22 21:42:28
[post_date_gmt] => 2020-05-22 21:42:28
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:38:41
[post_modified_gmt] => 2020-08-06 19:38:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1253
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[52] => WP_Post Object
(
[ID] => 1252
[post_author] => 6
[post_date] => 2020-05-22 21:41:17
[post_date_gmt] => 2020-05-22 21:41:17
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:25:32
[post_modified_gmt] => 2020-08-06 06:25:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1252
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[53] => WP_Post Object
(
[ID] => 1251
[post_author] => 6
[post_date] => 2020-05-22 21:39:48
[post_date_gmt] => 2020-05-22 21:39:48
[post_content] =>
[post_title] => CAVD Data & Materials Sharing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cavd-data-materials-sharing-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:40:50
[post_modified_gmt] => 2020-08-06 19:40:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1251
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[54] => WP_Post Object
(
[ID] => 1250
[post_author] => 6
[post_date] => 2020-05-22 21:38:31
[post_date_gmt] => 2020-05-22 21:38:31
[post_content] =>
[post_title] => CAVD Data & Materials Sharing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cavd-data-materials-sharing-agreement-2-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:41:55
[post_modified_gmt] => 2020-08-06 19:41:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1250
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[55] => WP_Post Object
(
[ID] => 1249
[post_author] => 6
[post_date] => 2020-05-22 21:37:42
[post_date_gmt] => 2020-05-22 21:37:42
[post_content] =>
[post_title] => MPP License Agreement with Gilead
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-gilead-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:22:26
[post_modified_gmt] => 2020-08-06 06:22:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1249
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[56] => WP_Post Object
(
[ID] => 1248
[post_author] => 6
[post_date] => 2020-05-22 21:36:47
[post_date_gmt] => 2020-05-22 21:36:47
[post_content] =>
[post_title] => Redacted Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:19:18
[post_modified_gmt] => 2020-08-06 06:19:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1248
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[57] => WP_Post Object
(
[ID] => 1247
[post_author] => 6
[post_date] => 2020-05-22 21:33:54
[post_date_gmt] => 2020-05-22 21:33:54
[post_content] =>
[post_title] => WHO Mutual Confidential Disclosure Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-mutual-confidential-disclosure-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:18:47
[post_modified_gmt] => 2020-08-06 06:18:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1247
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[58] => WP_Post Object
(
[ID] => 1245
[post_author] => 6
[post_date] => 2020-05-22 21:32:14
[post_date_gmt] => 2020-05-22 21:32:14
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:17:49
[post_modified_gmt] => 2020-08-06 06:17:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1245
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[59] => WP_Post Object
(
[ID] => 1244
[post_author] => 6
[post_date] => 2020-05-22 21:30:57
[post_date_gmt] => 2020-05-22 21:30:57
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:16:51
[post_modified_gmt] => 2020-08-06 06:16:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1244
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[60] => WP_Post Object
(
[ID] => 1243
[post_author] => 6
[post_date] => 2020-05-22 21:29:10
[post_date_gmt] => 2020-05-22 21:29:10
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-iia-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:15:56
[post_modified_gmt] => 2020-08-06 06:15:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1243
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[61] => WP_Post Object
(
[ID] => 1242
[post_author] => 6
[post_date] => 2020-05-22 21:26:04
[post_date_gmt] => 2020-05-22 21:26:04
[post_content] =>
[post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:45:06
[post_modified_gmt] => 2020-08-06 19:45:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1242
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[62] => WP_Post Object
(
[ID] => 1241
[post_author] => 6
[post_date] => 2020-05-22 21:24:25
[post_date_gmt] => 2020-05-22 21:24:25
[post_content] =>
[post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:13:20
[post_modified_gmt] => 2020-08-06 06:13:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1241
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[63] => WP_Post Object
(
[ID] => 1240
[post_author] => 6
[post_date] => 2020-05-22 21:22:47
[post_date_gmt] => 2020-05-22 21:22:47
[post_content] =>
[post_title] => Aridis-PATH Vaccine Formulation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:11:52
[post_modified_gmt] => 2020-08-06 06:11:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1240
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[64] => WP_Post Object
(
[ID] => 1239
[post_author] => 6
[post_date] => 2020-05-22 21:21:49
[post_date_gmt] => 2020-05-22 21:21:49
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:27:18
[post_modified_gmt] => 2020-08-06 06:27:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1239
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[65] => WP_Post Object
(
[ID] => 1238
[post_author] => 6
[post_date] => 2020-05-22 21:20:51
[post_date_gmt] => 2020-05-22 21:20:51
[post_content] =>
[post_title] => Redacted Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:29:07
[post_modified_gmt] => 2020-08-06 06:29:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1238
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[66] => WP_Post Object
(
[ID] => 1237
[post_author] => 6
[post_date] => 2020-05-22 21:19:08
[post_date_gmt] => 2020-05-22 21:19:08
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:29:51
[post_modified_gmt] => 2020-08-06 06:29:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1237
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[67] => WP_Post Object
(
[ID] => 1236
[post_author] => 6
[post_date] => 2020-05-22 21:17:57
[post_date_gmt] => 2020-05-22 21:17:57
[post_content] =>
[post_title] => WHO Template Material Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-template-material-transfer-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:30:25
[post_modified_gmt] => 2020-08-06 06:30:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1236
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[68] => WP_Post Object
(
[ID] => 1235
[post_author] => 6
[post_date] => 2020-05-22 21:01:14
[post_date_gmt] => 2020-05-22 21:01:14
[post_content] =>
[post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:33:13
[post_modified_gmt] => 2020-08-06 06:33:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1235
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[69] => WP_Post Object
(
[ID] => 1233
[post_author] => 6
[post_date] => 2020-05-22 21:00:08
[post_date_gmt] => 2020-05-22 21:00:08
[post_content] =>
[post_title] => Redacted Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:49:06
[post_modified_gmt] => 2020-08-06 19:49:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1233
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[70] => WP_Post Object
(
[ID] => 1232
[post_author] => 6
[post_date] => 2020-05-22 20:57:46
[post_date_gmt] => 2020-05-22 20:57:46
[post_content] =>
[post_title] => Redacted Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:35:49
[post_modified_gmt] => 2020-08-06 06:35:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1232
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[71] => WP_Post Object
(
[ID] => 1231
[post_author] => 6
[post_date] => 2020-05-22 20:54:50
[post_date_gmt] => 2020-05-22 20:54:50
[post_content] =>
[post_title] => CAVD Data & Materials Sharing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cavd-data-materials-sharing-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:37:41
[post_modified_gmt] => 2020-08-06 06:37:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1231
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[72] => WP_Post Object
(
[ID] => 1229
[post_author] => 6
[post_date] => 2020-05-22 20:51:35
[post_date_gmt] => 2020-05-22 20:51:35
[post_content] =>
[post_title] => MPP License Agreement with BMS & Aurobindo Pharma Ltd.
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-bms-aurobindo-pharma-ltd-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:39:20
[post_modified_gmt] => 2020-08-06 06:39:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1229
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[73] => WP_Post Object
(
[ID] => 1228
[post_author] => 6
[post_date] => 2020-05-22 20:49:20
[post_date_gmt] => 2020-05-22 20:49:20
[post_content] =>
[post_title] => MPP License Agreement with Gilead
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-gilead-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:52:03
[post_modified_gmt] => 2020-08-06 19:52:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1228
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[74] => WP_Post Object
(
[ID] => 1227
[post_author] => 6
[post_date] => 2020-05-22 20:48:27
[post_date_gmt] => 2020-05-22 20:48:27
[post_content] =>
[post_title] => Ebola WHO-Manufacturer LOA (Annex)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ebola-who-manufacturer-loa-annex
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:52:47
[post_modified_gmt] => 2020-08-06 19:52:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1227
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[75] => WP_Post Object
(
[ID] => 1226
[post_author] => 6
[post_date] => 2020-05-22 20:47:05
[post_date_gmt] => 2020-05-22 20:47:05
[post_content] =>
[post_title] => WHO Template Material Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-template-material-transfer-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:44:21
[post_modified_gmt] => 2020-08-06 06:44:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1226
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[76] => WP_Post Object
(
[ID] => 1225
[post_author] => 6
[post_date] => 2020-05-22 20:43:20
[post_date_gmt] => 2020-05-22 20:43:20
[post_content] =>
[post_title] => WHO Template Material Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-template-material-transfer-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:45:39
[post_modified_gmt] => 2020-08-06 06:45:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1225
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[77] => WP_Post Object
(
[ID] => 1223
[post_author] => 6
[post_date] => 2020-05-22 20:14:40
[post_date_gmt] => 2020-05-22 20:14:40
[post_content] =>
[post_title] => Ten Principles for Socially Responsible Licensing, by Netherlands Federation of University Medical Centers (June 2019)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ten-principles-for-socially-responsible-licensing-by-netherlands-federation-of-university-medical-centers-june-2019-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:46:21
[post_modified_gmt] => 2020-08-06 06:46:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1223
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[78] => WP_Post Object
(
[ID] => 1222
[post_author] => 6
[post_date] => 2020-05-22 20:12:04
[post_date_gmt] => 2020-05-22 20:12:04
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfpi3-template-funding-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:47:07
[post_modified_gmt] => 2020-08-06 06:47:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1222
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[79] => WP_Post Object
(
[ID] => 1221
[post_author] => 6
[post_date] => 2020-05-22 20:09:53
[post_date_gmt] => 2020-05-22 20:09:53
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfpi3-template-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:55:03
[post_modified_gmt] => 2020-08-06 19:55:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1221
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[80] => WP_Post Object
(
[ID] => 1220
[post_author] => 6
[post_date] => 2020-05-22 20:05:59
[post_date_gmt] => 2020-05-22 20:05:59
[post_content] =>
[post_title] => Redacted Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:48:16
[post_modified_gmt] => 2020-08-06 06:48:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[81] => WP_Post Object
(
[ID] => 1218
[post_author] => 6
[post_date] => 2020-05-22 20:04:53
[post_date_gmt] => 2020-05-22 20:04:53
[post_content] =>
[post_title] => CARB-X Research Subaward Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => carb-x-research-subaward-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 19:57:30
[post_modified_gmt] => 2020-08-06 19:57:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1218
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[82] => WP_Post Object
(
[ID] => 1217
[post_author] => 6
[post_date] => 2020-05-22 20:00:26
[post_date_gmt] => 2020-05-22 20:00:26
[post_content] =>
[post_title] => EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => edctp2-policy-on-clinical-trials-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:16:02
[post_modified_gmt] => 2020-08-06 07:16:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1217
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[83] => WP_Post Object
(
[ID] => 1216
[post_author] => 6
[post_date] => 2020-05-22 19:58:08
[post_date_gmt] => 2020-05-22 19:58:08
[post_content] =>
[post_title] => EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => edctp2-policy-on-clinical-trials
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:54:51
[post_modified_gmt] => 2020-08-06 06:54:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1216
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[84] => WP_Post Object
(
[ID] => 1215
[post_author] => 6
[post_date] => 2020-05-22 19:56:47
[post_date_gmt] => 2020-05-22 19:56:47
[post_content] =>
[post_title] => EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => edctp2-policy-on-clinical-trials-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:56:31
[post_modified_gmt] => 2020-08-06 06:56:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1215
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[85] => WP_Post Object
(
[ID] => 1214
[post_author] => 6
[post_date] => 2020-05-22 19:55:41
[post_date_gmt] => 2020-05-22 19:55:41
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-14
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:57:53
[post_modified_gmt] => 2020-08-06 06:57:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1214
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[86] => WP_Post Object
(
[ID] => 1211
[post_author] => 6
[post_date] => 2020-05-22 19:50:22
[post_date_gmt] => 2020-05-22 19:50:22
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:58:52
[post_modified_gmt] => 2020-08-06 06:58:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1211
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[87] => WP_Post Object
(
[ID] => 1210
[post_author] => 6
[post_date] => 2020-05-22 19:49:19
[post_date_gmt] => 2020-05-22 19:49:19
[post_content] =>
[post_title] => Ten Principles for Socially Responsible Licensing, by Netherlands Federation of University Medical Centers (June 2019)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ten-principles-for-socially-responsible-licensing-by-netherlands-federation-of-university-medical-centers-june-2019
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:59:22
[post_modified_gmt] => 2020-08-06 06:59:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1210
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[88] => WP_Post Object
(
[ID] => 1207
[post_author] => 6
[post_date] => 2020-05-22 19:42:36
[post_date_gmt] => 2020-05-22 19:42:36
[post_content] =>
[post_title] => MPP License Agreement with Pfizer re Sutezolid
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-pfizer-re-sutezolid
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 06:59:52
[post_modified_gmt] => 2020-08-06 06:59:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1207
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[89] => WP_Post Object
(
[ID] => 1206
[post_author] => 6
[post_date] => 2020-05-22 19:37:27
[post_date_gmt] => 2020-05-22 19:37:27
[post_content] =>
[post_title] => Gates Global Access Commitment & Humanitarian License
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-global-access-commitment-and-humanitarian-license
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:00:51
[post_modified_gmt] => 2020-08-06 07:00:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1206
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[90] => WP_Post Object
(
[ID] => 1200
[post_author] => 6
[post_date] => 2020-05-22 19:35:05
[post_date_gmt] => 2020-05-22 19:35:05
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 20:02:26
[post_modified_gmt] => 2020-08-06 20:02:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1200
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[91] => WP_Post Object
(
[ID] => 1205
[post_author] => 6
[post_date] => 2020-05-22 19:33:17
[post_date_gmt] => 2020-05-22 19:33:17
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:04:45
[post_modified_gmt] => 2020-08-06 07:04:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1205
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[92] => WP_Post Object
(
[ID] => 1204
[post_author] => 6
[post_date] => 2020-05-22 19:31:46
[post_date_gmt] => 2020-05-22 19:31:46
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:06:42
[post_modified_gmt] => 2020-08-06 07:06:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1204
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[93] => WP_Post Object
(
[ID] => 1203
[post_author] => 6
[post_date] => 2020-05-22 19:30:52
[post_date_gmt] => 2020-05-22 19:30:52
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:07:29
[post_modified_gmt] => 2020-08-06 07:07:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1203
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[94] => WP_Post Object
(
[ID] => 1202
[post_author] => 6
[post_date] => 2020-05-22 19:28:49
[post_date_gmt] => 2020-05-22 19:28:49
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-09-06 23:38:12
[post_modified_gmt] => 2020-09-06 23:38:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1202
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[95] => WP_Post Object
(
[ID] => 1201
[post_author] => 6
[post_date] => 2020-05-22 19:26:29
[post_date_gmt] => 2020-05-22 19:26:29
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:09:26
[post_modified_gmt] => 2020-08-06 07:09:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1201
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[96] => WP_Post Object
(
[ID] => 1199
[post_author] => 6
[post_date] => 2020-05-22 19:21:57
[post_date_gmt] => 2020-05-22 19:21:57
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:11:10
[post_modified_gmt] => 2020-08-06 07:11:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1199
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[97] => WP_Post Object
(
[ID] => 1198
[post_author] => 6
[post_date] => 2020-05-22 19:12:54
[post_date_gmt] => 2020-05-22 19:12:54
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:12:41
[post_modified_gmt] => 2020-08-06 07:12:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1198
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[98] => WP_Post Object
(
[ID] => 1193
[post_author] => 6
[post_date] => 2020-05-22 02:10:10
[post_date_gmt] => 2020-05-22 02:10:10
[post_content] =>
[post_title] => Aridis-PATH Vaccine Formulation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-04 04:18:05
[post_modified_gmt] => 2020-08-04 04:18:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1193
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[99] => WP_Post Object
(
[ID] => 1190
[post_author] => 6
[post_date] => 2020-05-22 01:59:48
[post_date_gmt] => 2020-05-22 01:59:48
[post_content] =>
[post_title] => Aridis-PATH Vaccine Formulation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:13:53
[post_modified_gmt] => 2020-08-06 07:13:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1190
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[100] => WP_Post Object
(
[ID] => 1187
[post_author] => 6
[post_date] => 2020-05-22 01:56:10
[post_date_gmt] => 2020-05-22 01:56:10
[post_content] =>
[post_title] => CARB-X Research Subaward Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => carb-x-research-subaward-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:15:18
[post_modified_gmt] => 2020-08-06 07:15:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1187
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[101] => WP_Post Object
(
[ID] => 1186
[post_author] => 6
[post_date] => 2020-05-22 00:11:20
[post_date_gmt] => 2020-05-22 00:11:20
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-iia-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:19:26
[post_modified_gmt] => 2020-08-06 07:19:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1186
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[102] => WP_Post Object
(
[ID] => 1185
[post_author] => 6
[post_date] => 2020-05-22 00:10:01
[post_date_gmt] => 2020-05-22 00:10:01
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:19:08
[post_modified_gmt] => 2020-08-06 07:19:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1185
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[103] => WP_Post Object
(
[ID] => 1184
[post_author] => 6
[post_date] => 2020-05-22 00:08:17
[post_date_gmt] => 2020-05-22 00:08:17
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:18:30
[post_modified_gmt] => 2020-08-06 07:18:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1184
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[104] => WP_Post Object
(
[ID] => 1183
[post_author] => 6
[post_date] => 2020-05-22 00:06:26
[post_date_gmt] => 2020-05-22 00:06:26
[post_content] =>
[post_title] => MPP License Agreement with AbbVie (LPV r)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-abbvie
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:20:18
[post_modified_gmt] => 2020-08-06 07:20:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1183
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[105] => WP_Post Object
(
[ID] => 1182
[post_author] => 6
[post_date] => 2020-05-22 00:02:42
[post_date_gmt] => 2020-05-22 00:02:42
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-iia-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 20:22:28
[post_modified_gmt] => 2020-08-06 20:22:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1182
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[106] => WP_Post Object
(
[ID] => 1179
[post_author] => 6
[post_date] => 2020-05-21 23:58:21
[post_date_gmt] => 2020-05-21 23:58:21
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 20:23:03
[post_modified_gmt] => 2020-08-06 20:23:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1179
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[107] => WP_Post Object
(
[ID] => 1178
[post_author] => 6
[post_date] => 2020-05-21 23:55:50
[post_date_gmt] => 2020-05-21 23:55:50
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:23:22
[post_modified_gmt] => 2020-08-06 07:23:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1178
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[108] => WP_Post Object
(
[ID] => 1177
[post_author] => 6
[post_date] => 2020-05-21 23:53:56
[post_date_gmt] => 2020-05-21 23:53:56
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:24:45
[post_modified_gmt] => 2020-08-06 07:24:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1177
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[109] => WP_Post Object
(
[ID] => 1176
[post_author] => 6
[post_date] => 2020-05-21 23:52:12
[post_date_gmt] => 2020-05-21 23:52:12
[post_content] =>
[post_title] => Aridis-PATH Vaccine Formulation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:26:01
[post_modified_gmt] => 2020-08-06 07:26:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1176
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[110] => WP_Post Object
(
[ID] => 1175
[post_author] => 6
[post_date] => 2020-05-21 23:44:57
[post_date_gmt] => 2020-05-21 23:44:57
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:28:09
[post_modified_gmt] => 2020-08-06 07:28:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1175
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[111] => WP_Post Object
(
[ID] => 1173
[post_author] => 6
[post_date] => 2020-05-21 23:37:42
[post_date_gmt] => 2020-05-21 23:37:42
[post_content] =>
[post_title] => CARB-X Research Subaward Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => carb-x-research-subaward-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 20:28:01
[post_modified_gmt] => 2020-08-06 20:28:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1173
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[112] => WP_Post Object
(
[ID] => 1172
[post_author] => 6
[post_date] => 2020-05-21 23:35:57
[post_date_gmt] => 2020-05-21 23:35:57
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:48:07
[post_modified_gmt] => 2020-08-06 07:48:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1172
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[113] => WP_Post Object
(
[ID] => 1171
[post_author] => 6
[post_date] => 2020-05-21 23:33:24
[post_date_gmt] => 2020-05-21 23:33:24
[post_content] =>
[post_title] => IMI 1 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-1-model-grant-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:34:16
[post_modified_gmt] => 2020-08-06 07:34:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1171
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[114] => WP_Post Object
(
[ID] => 1170
[post_author] => 6
[post_date] => 2020-05-21 23:28:59
[post_date_gmt] => 2020-05-21 23:28:59
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:46:46
[post_modified_gmt] => 2020-08-06 07:46:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1170
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[115] => WP_Post Object
(
[ID] => 1168
[post_author] => 6
[post_date] => 2020-05-21 23:26:48
[post_date_gmt] => 2020-05-21 23:26:48
[post_content] =>
[post_title] => NIH Model License Agreement for Use by Non-Profit
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-model-license-agreement-for-use-by-non-profit-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:45:59
[post_modified_gmt] => 2020-08-06 07:45:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1168
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[116] => WP_Post Object
(
[ID] => 1166
[post_author] => 6
[post_date] => 2020-05-21 23:26:07
[post_date_gmt] => 2020-05-21 23:26:07
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:45:40
[post_modified_gmt] => 2020-08-06 07:45:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1166
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[117] => WP_Post Object
(
[ID] => 1165
[post_author] => 6
[post_date] => 2020-05-21 23:23:57
[post_date_gmt] => 2020-05-21 23:23:57
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:44:57
[post_modified_gmt] => 2020-08-06 07:44:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1165
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[118] => WP_Post Object
(
[ID] => 1164
[post_author] => 6
[post_date] => 2020-05-21 23:22:37
[post_date_gmt] => 2020-05-21 23:22:37
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-iia
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 20:30:07
[post_modified_gmt] => 2020-08-06 20:30:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1164
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[119] => WP_Post Object
(
[ID] => 1162
[post_author] => 6
[post_date] => 2020-05-21 23:19:43
[post_date_gmt] => 2020-05-21 23:19:43
[post_content] =>
[post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:43:25
[post_modified_gmt] => 2020-08-06 07:43:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1162
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[120] => WP_Post Object
(
[ID] => 1160
[post_author] => 6
[post_date] => 2020-05-21 23:18:03
[post_date_gmt] => 2020-05-21 23:18:03
[post_content] =>
[post_title] => Aridis-PATH Vaccine Formulation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:41:09
[post_modified_gmt] => 2020-08-06 07:41:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1160
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[121] => WP_Post Object
(
[ID] => 1159
[post_author] => 6
[post_date] => 2020-05-21 23:14:15
[post_date_gmt] => 2020-05-21 23:14:15
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:39:58
[post_modified_gmt] => 2020-08-06 07:39:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1159
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[122] => WP_Post Object
(
[ID] => 1158
[post_author] => 6
[post_date] => 2020-05-21 23:12:13
[post_date_gmt] => 2020-05-21 23:12:13
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:38:32
[post_modified_gmt] => 2020-08-06 07:38:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1158
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[123] => WP_Post Object
(
[ID] => 1156
[post_author] => 6
[post_date] => 2020-05-21 23:10:39
[post_date_gmt] => 2020-05-21 23:10:39
[post_content] =>
[post_title] => WHO Standard Framework Memorandum of Understanding
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-standard-framework-memorandum-of-understanding
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:36:26
[post_modified_gmt] => 2020-08-06 07:36:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1156
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[124] => WP_Post Object
(
[ID] => 1155
[post_author] => 6
[post_date] => 2020-05-21 23:09:39
[post_date_gmt] => 2020-05-21 23:09:39
[post_content] =>
[post_title] => WHO Template Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => template-collaboration-agreement-with-who
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:13:07
[post_modified_gmt] => 2020-08-06 08:13:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1155
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[125] => WP_Post Object
(
[ID] => 1150
[post_author] => 6
[post_date] => 2020-05-21 22:53:25
[post_date_gmt] => 2020-05-21 22:53:25
[post_content] =>
[post_title] => Redacted Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:15:03
[post_modified_gmt] => 2020-08-06 08:15:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1150
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[126] => WP_Post Object
(
[ID] => 1147
[post_author] => 6
[post_date] => 2020-05-21 22:50:33
[post_date_gmt] => 2020-05-21 22:50:33
[post_content] =>
[post_title] => IMI 1 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-1-model-grant-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:15:52
[post_modified_gmt] => 2020-08-06 08:15:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1147
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[127] => WP_Post Object
(
[ID] => 1145
[post_author] => 6
[post_date] => 2020-05-21 22:48:08
[post_date_gmt] => 2020-05-21 22:48:08
[post_content] =>
[post_title] => Gilead HCV License Agreement with Indian Generic Manufacturers
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:17:09
[post_modified_gmt] => 2020-08-06 08:17:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1145
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[128] => WP_Post Object
(
[ID] => 1143
[post_author] => 6
[post_date] => 2020-05-21 22:46:30
[post_date_gmt] => 2020-05-21 22:46:30
[post_content] =>
[post_title] => MPP License Agreement with Gilead
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-gilead-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:18:12
[post_modified_gmt] => 2020-08-06 08:18:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1143
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[129] => WP_Post Object
(
[ID] => 1141
[post_author] => 6
[post_date] => 2020-05-21 22:43:46
[post_date_gmt] => 2020-05-21 22:43:46
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:19:21
[post_modified_gmt] => 2020-08-06 08:19:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1141
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[130] => WP_Post Object
(
[ID] => 1140
[post_author] => 6
[post_date] => 2020-05-21 22:37:27
[post_date_gmt] => 2020-05-21 22:37:27
[post_content] =>
[post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:21:40
[post_modified_gmt] => 2020-08-06 08:21:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1140
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[131] => WP_Post Object
(
[ID] => 1139
[post_author] => 6
[post_date] => 2020-05-21 22:35:04
[post_date_gmt] => 2020-05-21 22:35:04
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:22:26
[post_modified_gmt] => 2020-08-06 08:22:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1139
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[132] => WP_Post Object
(
[ID] => 1137
[post_author] => 6
[post_date] => 2020-05-21 22:22:50
[post_date_gmt] => 2020-05-21 22:22:50
[post_content] =>
[post_title] => Gilead HCV License Agreement with Indian Generic Manufacturers
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:25:03
[post_modified_gmt] => 2020-08-06 08:25:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1137
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[133] => WP_Post Object
(
[ID] => 1135
[post_author] => 6
[post_date] => 2020-05-21 22:19:46
[post_date_gmt] => 2020-05-21 22:19:46
[post_content] =>
[post_title] => NIH Model License Agreement for Use by Non-Profit
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-model-license-agreement-for-use-by-non-profit
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:25:31
[post_modified_gmt] => 2020-08-06 08:25:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1135
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[134] => WP_Post Object
(
[ID] => 1134
[post_author] => 6
[post_date] => 2020-05-21 22:00:36
[post_date_gmt] => 2020-05-21 22:00:36
[post_content] =>
[post_title] => CAVD Data & Materials Sharing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cavd-data-materials-sharing-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:25:48
[post_modified_gmt] => 2020-08-06 08:25:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1134
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[135] => WP_Post Object
(
[ID] => 1132
[post_author] => 6
[post_date] => 2020-05-21 21:58:10
[post_date_gmt] => 2020-05-21 21:58:10
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:27:59
[post_modified_gmt] => 2020-08-06 08:27:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1132
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[136] => WP_Post Object
(
[ID] => 1131
[post_author] => 6
[post_date] => 2020-05-21 21:56:27
[post_date_gmt] => 2020-05-21 21:56:27
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-%c2%a725-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:12:00
[post_modified_gmt] => 2020-08-06 08:12:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1131
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[137] => WP_Post Object
(
[ID] => 1129
[post_author] => 6
[post_date] => 2020-05-21 21:51:51
[post_date_gmt] => 2020-05-21 21:51:51
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement §25.2
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:10:01
[post_modified_gmt] => 2020-08-06 08:10:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1129
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[138] => WP_Post Object
(
[ID] => 1128
[post_author] => 6
[post_date] => 2020-05-21 21:50:04
[post_date_gmt] => 2020-05-21 21:50:04
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:09:28
[post_modified_gmt] => 2020-08-06 08:09:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1128
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[139] => WP_Post Object
(
[ID] => 1127
[post_author] => 6
[post_date] => 2020-05-21 21:47:49
[post_date_gmt] => 2020-05-21 21:47:49
[post_content] =>
[post_title] => BU Startup Exclusive License
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bu-startup-exclusive-license
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:08:46
[post_modified_gmt] => 2020-08-06 08:08:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1127
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[140] => WP_Post Object
(
[ID] => 1125
[post_author] => 6
[post_date] => 2020-05-21 21:44:59
[post_date_gmt] => 2020-05-21 21:44:59
[post_content] =>
[post_title] => MPP Sublicense Agreement under AbbVie-MPP License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:08:05
[post_modified_gmt] => 2020-08-06 08:08:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1125
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[141] => WP_Post Object
(
[ID] => 1124
[post_author] => 6
[post_date] => 2020-05-21 21:41:21
[post_date_gmt] => 2020-05-21 21:41:21
[post_content] =>
[post_title] => MPP Amended and Restated Sublicense and Technology Transfer Agreement under BMS-MPP License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:06:09
[post_modified_gmt] => 2020-08-06 08:06:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1124
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[142] => WP_Post Object
(
[ID] => 1123
[post_author] => 6
[post_date] => 2020-05-21 21:37:52
[post_date_gmt] => 2020-05-21 21:37:52
[post_content] =>
[post_title] => MPP License Agreement with ViiV on Dolutegravir for Adults
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-viiv-on-dolutegravir-for-adults
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:02:41
[post_modified_gmt] => 2020-08-06 08:02:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1123
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[143] => WP_Post Object
(
[ID] => 1122
[post_author] => 6
[post_date] => 2020-05-21 21:30:19
[post_date_gmt] => 2020-05-21 21:30:19
[post_content] =>
[post_title] => MPP License Agreement with BMS & Aurobindo Pharma Ltd.
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-bms-aurobindo-pharma-ltd
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:02:05
[post_modified_gmt] => 2020-08-06 08:02:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1122
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[144] => WP_Post Object
(
[ID] => 1120
[post_author] => 6
[post_date] => 2020-05-21 21:28:37
[post_date_gmt] => 2020-05-21 21:28:37
[post_content] =>
[post_title] => MPP Sublicense Agreement under AbbVie-MPP License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-sublicense-agreement-under-abbvie-mpp-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 08:00:43
[post_modified_gmt] => 2020-08-06 08:00:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1120
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[145] => WP_Post Object
(
[ID] => 1118
[post_author] => 6
[post_date] => 2020-05-21 21:24:00
[post_date_gmt] => 2020-05-21 21:24:00
[post_content] =>
[post_title] => MPP License Agreement with AbbVie (LPV r)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpps-license-agreement-with-abbvie
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:59:29
[post_modified_gmt] => 2020-08-06 07:59:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1118
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[146] => WP_Post Object
(
[ID] => 1117
[post_author] => 6
[post_date] => 2020-05-21 21:17:31
[post_date_gmt] => 2020-05-21 21:17:31
[post_content] =>
[post_title] => MPP License Agreement with University of Liverpool
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpps-license-agreement-with-university-of-liverpool
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:58:09
[post_modified_gmt] => 2020-08-06 07:58:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1117
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[147] => WP_Post Object
(
[ID] => 1114
[post_author] => 6
[post_date] => 2020-05-21 21:13:15
[post_date_gmt] => 2020-05-21 21:13:15
[post_content] =>
[post_title] => MPP License Agreement with Gilead
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-gilead
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:55:36
[post_modified_gmt] => 2020-08-06 07:55:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1114
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[148] => WP_Post Object
(
[ID] => 1113
[post_author] => 6
[post_date] => 2020-05-21 21:09:47
[post_date_gmt] => 2020-05-21 21:09:47
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-15
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:54:21
[post_modified_gmt] => 2020-08-06 07:54:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1113
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[149] => WP_Post Object
(
[ID] => 1112
[post_author] => 6
[post_date] => 2020-05-21 21:06:05
[post_date_gmt] => 2020-05-21 21:06:05
[post_content] =>
[post_title] => License and Collaboration Agreement between Merck and Bioprotection Systems Corp. (wholly owned subsidiary of NewLink Genetic Corporation)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:53:41
[post_modified_gmt] => 2020-08-06 07:53:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1112
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[150] => WP_Post Object
(
[ID] => 1111
[post_author] => 6
[post_date] => 2020-05-21 21:03:23
[post_date_gmt] => 2020-05-21 21:03:23
[post_content] =>
[post_title] => IMI 1 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-1-model-grant-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:53:03
[post_modified_gmt] => 2020-08-06 07:53:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1111
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[151] => WP_Post Object
(
[ID] => 1109
[post_author] => 6
[post_date] => 2020-05-21 21:01:18
[post_date_gmt] => 2020-05-21 21:01:18
[post_content] =>
[post_title] => CAVD Data & Materials Sharing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cavd-data-materials-sharing-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-04 04:28:44
[post_modified_gmt] => 2020-08-04 04:28:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1109
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[152] => WP_Post Object
(
[ID] => 1108
[post_author] => 6
[post_date] => 2020-05-21 20:59:47
[post_date_gmt] => 2020-05-21 20:59:47
[post_content] =>
[post_title] => WHO Template Material Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-template-material-transfer-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:51:26
[post_modified_gmt] => 2020-08-06 07:51:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1108
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[153] => WP_Post Object
(
[ID] => 1107
[post_author] => 6
[post_date] => 2020-05-21 20:57:25
[post_date_gmt] => 2020-05-21 20:57:25
[post_content] =>
[post_title] => Lambert Agreement D
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:50:28
[post_modified_gmt] => 2020-08-06 07:50:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1107
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[154] => WP_Post Object
(
[ID] => 996
[post_author] => 7
[post_date] => 2020-05-18 19:58:18
[post_date_gmt] => 2020-05-18 19:58:18
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:49:31
[post_modified_gmt] => 2020-08-06 07:49:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=996
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[invalid_get] =>
[is_text_search] =>
[has_agreement_filters] =>
[has_any_agreement_filter] => Array
(
)
[found_agreements] =>
[has_provision_filters] =>
[found_provisions] => 1
[lbl_quick_search:GHIAA2019\MapguideSearch:private] => Search results for:
[lbl_issue:GHIAA2019\MapguideSearch:private] => Issue:
[lbl_key_term:GHIAA2019\MapguideSearch:private] => Key Term:
[lbl_partner_type:GHIAA2019\MapguideSearch:private] => Partner Type:
[lbl_technology:GHIAA2019\MapguideSearch:private] => Technology:
[lbl_development_stage:GHIAA2019\MapguideSearch:private] => Development Stage:
[issues_by_id:GHIAA2019\MapguideSearch:private] => Array
(
[46] => WP_Term Object
(
[term_id] => 46
[name] => Access to medicines
[slug] => access-to-medicines
[term_group] => 0
[term_taxonomy_id] => 46
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[91] => WP_Term Object
(
[term_id] => 91
[name] => Access to results
[slug] => access-results
[term_group] => 0
[term_taxonomy_id] => 91
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 9
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[100] => WP_Term Object
(
[term_id] => 100
[name] => Affordable or reasonable pricing
[slug] => pricing
[term_group] => 0
[term_taxonomy_id] => 100
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 1
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[55] => WP_Term Object
(
[term_id] => 55
[name] => Annexes
[slug] => annexes
[term_group] => 0
[term_taxonomy_id] => 55
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[66] => WP_Term Object
(
[term_id] => 66
[name] => Benefit/revenue sharing
[slug] => benefit-revenue-sharing
[term_group] => 0
[term_taxonomy_id] => 66
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 3
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[53] => WP_Term Object
(
[term_id] => 53
[name] => Business model
[slug] => business-model
[term_group] => 0
[term_taxonomy_id] => 53
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 1
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[58] => WP_Term Object
(
[term_id] => 58
[name] => Commercialization strategy
[slug] => commercialization-strategy
[term_group] => 0
[term_taxonomy_id] => 58
[taxonomy] => issue
[description] =>
[parent] => 55
[count] => 0
[filter] => raw
[parent_name] => Annexes
[parent_slug] => annexes
)
[84] => WP_Term Object
(
[term_id] => 84
[name] => Confidentiality
[slug] => confidentiality
[term_group] => 0
[term_taxonomy_id] => 84
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 20
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[59] => WP_Term Object
(
[term_id] => 59
[name] => Conflict of Interest
[slug] => conflict-of-interest
[term_group] => 0
[term_taxonomy_id] => 59
[taxonomy] => issue
[description] =>
[parent] => 54
[count] => 0
[filter] => raw
[parent_name] => Other
[parent_slug] => other
)
[51] => WP_Term Object
(
[term_id] => 51
[name] => Consortium structure & management
[slug] => consortium-structure
[term_group] => 0
[term_taxonomy_id] => 51
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 5
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[95] => WP_Term Object
(
[term_id] => 95
[name] => Data & material sharing
[slug] => data-material-sharing
[term_group] => 0
[term_taxonomy_id] => 95
[taxonomy] => issue
[description] =>
[parent] => 47
[count] => 0
[filter] => raw
[parent_name] => Open sciences & open data
[parent_slug] => open-science
)
[82] => WP_Term Object
(
[term_id] => 82
[name] => Data management
[slug] => data-management
[term_group] => 0
[term_taxonomy_id] => 82
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 4
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[267] => WP_Term Object
(
[term_id] => 267
[name] => Dispute resolution
[slug] => dispute-resolution
[term_group] => 0
[term_taxonomy_id] => 267
[taxonomy] => issue
[description] =>
[parent] => 54
[count] => 1
[filter] => raw
[parent_name] => Other
[parent_slug] => other
)
[72] => WP_Term Object
(
[term_id] => 72
[name] => Effect of termination
[slug] => effect-of-termination
[term_group] => 0
[term_taxonomy_id] => 72
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 2
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[101] => WP_Term Object
(
[term_id] => 101
[name] => Equitable access
[slug] => equitable-access
[term_group] => 0
[term_taxonomy_id] => 101
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 13
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[83] => WP_Term Object
(
[term_id] => 83
[name] => Exceptions and limitations to the confidentiality obligations
[slug] => exceptions-confidentiality
[term_group] => 0
[term_taxonomy_id] => 83
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 7
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[93] => WP_Term Object
(
[term_id] => 93
[name] => Exceptions or limitations to the IP ownership rules
[slug] => exceptions-ip-ownership
[term_group] => 0
[term_taxonomy_id] => 93
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 1
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[92] => WP_Term Object
(
[term_id] => 92
[name] => Exploitation of results
[slug] => exploitation-results
[term_group] => 0
[term_taxonomy_id] => 92
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 9
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[103] => WP_Term Object
(
[term_id] => 103
[name] => Funder step-in rights
[slug] => funder-step-in
[term_group] => 0
[term_taxonomy_id] => 103
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 1
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[57] => WP_Term Object
(
[term_id] => 57
[name] => Global access plans
[slug] => global-access-plans
[term_group] => 0
[term_taxonomy_id] => 57
[taxonomy] => issue
[description] =>
[parent] => 55
[count] => 0
[filter] => raw
[parent_name] => Annexes
[parent_slug] => annexes
)
[80] => WP_Term Object
(
[term_id] => 80
[name] => Indemnity / indemnification
[slug] => indemnity
[term_group] => 0
[term_taxonomy_id] => 80
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 8
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[257] => WP_Term Object
(
[term_id] => 257
[name] => Information sharing
[slug] => information-sharing-information-sharing
[term_group] => 0
[term_taxonomy_id] => 257
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 2
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[49] => WP_Term Object
(
[term_id] => 49
[name] => Information sharing & data safety
[slug] => information-sharing
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 3
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[109] => WP_Term Object
(
[term_id] => 109
[name] => Insurance
[slug] => insurance
[term_group] => 0
[term_taxonomy_id] => 109
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 1
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[48] => WP_Term Object
(
[term_id] => 48
[name] => IP ownership & licensing
[slug] => ip-ownership
[term_group] => 0
[term_taxonomy_id] => 48
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 1
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[50] => WP_Term Object
(
[term_id] => 50
[name] => Liability
[slug] => liability
[term_group] => 0
[term_taxonomy_id] => 50
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[79] => WP_Term Object
(
[term_id] => 79
[name] => Limitation of liability/damage
[slug] => limitation-of-liability
[term_group] => 0
[term_taxonomy_id] => 79
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 10
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[85] => WP_Term Object
(
[term_id] => 85
[name] => Material transfer
[slug] => material-transfer
[term_group] => 0
[term_taxonomy_id] => 85
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 4
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[98] => WP_Term Object
(
[term_id] => 98
[name] => Open data
[slug] => open-data
[term_group] => 0
[term_taxonomy_id] => 98
[taxonomy] => issue
[description] =>
[parent] => 47
[count] => 8
[filter] => raw
[parent_name] => Open sciences & open data
[parent_slug] => open-science
)
[97] => WP_Term Object
(
[term_id] => 97
[name] => Open sciences
[slug] => open-sciences
[term_group] => 0
[term_taxonomy_id] => 97
[taxonomy] => issue
[description] =>
[parent] => 47
[count] => 8
[filter] => raw
[parent_name] => Open sciences & open data
[parent_slug] => open-science
)
[47] => WP_Term Object
(
[term_id] => 47
[name] => Open sciences & open data
[slug] => open-science
[term_group] => 0
[term_taxonomy_id] => 47
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[54] => WP_Term Object
(
[term_id] => 54
[name] => Other
[slug] => other
[term_group] => 0
[term_taxonomy_id] => 54
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[102] => WP_Term Object
(
[term_id] => 102
[name] => Outbreak preparedness
[slug] => outbreak-preparedness
[term_group] => 0
[term_taxonomy_id] => 102
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 1
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[87] => WP_Term Object
(
[term_id] => 87
[name] => Ownership of background IP
[slug] => ownership-background-ip
[term_group] => 0
[term_taxonomy_id] => 87
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 8
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[89] => WP_Term Object
(
[term_id] => 89
[name] => Ownership of results
[slug] => ownership-results
[term_group] => 0
[term_taxonomy_id] => 89
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 14
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[266] => WP_Term Object
(
[term_id] => 266
[name] => Pandemic Products
[slug] => pandemic-products
[term_group] => 0
[term_taxonomy_id] => 266
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 1
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[104] => WP_Term Object
(
[term_id] => 104
[name] => Policy considerations
[slug] => policy-considerations
[term_group] => 0
[term_taxonomy_id] => 104
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 1
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[90] => WP_Term Object
(
[term_id] => 90
[name] => Protection of results
[slug] => protection-results
[term_group] => 0
[term_taxonomy_id] => 90
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 8
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[107] => WP_Term Object
(
[term_id] => 107
[name] => Public health licenses
[slug] => public-health-licenses
[term_group] => 0
[term_taxonomy_id] => 107
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 2
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[96] => WP_Term Object
(
[term_id] => 96
[name] => Publication
[slug] => publication
[term_group] => 0
[term_taxonomy_id] => 96
[taxonomy] => issue
[description] =>
[parent] => 47
[count] => 7
[filter] => raw
[parent_name] => Open sciences & open data
[parent_slug] => open-science
)
[56] => WP_Term Object
(
[term_id] => 56
[name] => Regulatory strategy
[slug] => regulatory-strategy
[term_group] => 0
[term_taxonomy_id] => 56
[taxonomy] => issue
[description] =>
[parent] => 55
[count] => 0
[filter] => raw
[parent_name] => Annexes
[parent_slug] => annexes
)
[64] => WP_Term Object
(
[term_id] => 64
[name] => Reporting
[slug] => reporting
[term_group] => 0
[term_taxonomy_id] => 64
[taxonomy] => issue
[description] =>
[parent] => 54
[count] => 0
[filter] => raw
[parent_name] => Other
[parent_slug] => other
)
[69] => WP_Term Object
(
[term_id] => 69
[name] => Risk sharing
[slug] => risk-sharing
[term_group] => 0
[term_taxonomy_id] => 69
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 0
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[70] => WP_Term Object
(
[term_id] => 70
[name] => Royalties & payments
[slug] => royalties-and-payments
[term_group] => 0
[term_taxonomy_id] => 70
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 2
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[108] => WP_Term Object
(
[term_id] => 108
[name] => Sublicenses
[slug] => sublicensee
[term_group] => 0
[term_taxonomy_id] => 108
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 2
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[62] => WP_Term Object
(
[term_id] => 62
[name] => Survival
[slug] => survival
[term_group] => 0
[term_taxonomy_id] => 62
[taxonomy] => issue
[description] =>
[parent] => 54
[count] => 0
[filter] => raw
[parent_name] => Other
[parent_slug] => other
)
[86] => WP_Term Object
(
[term_id] => 86
[name] => Technology transfer
[slug] => technology-transfer
[term_group] => 0
[term_taxonomy_id] => 86
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 6
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[52] => WP_Term Object
(
[term_id] => 52
[name] => Term & termination
[slug] => term-and-termination
[term_group] => 0
[term_taxonomy_id] => 52
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[76] => WP_Term Object
(
[term_id] => 76
[name] => Term of agreement
[slug] => term-of-agreement
[term_group] => 0
[term_taxonomy_id] => 76
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 4
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[74] => WP_Term Object
(
[term_id] => 74
[name] => Termination & withdrawal
[slug] => termination-and-withdrawal
[term_group] => 0
[term_taxonomy_id] => 74
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 6
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[88] => WP_Term Object
(
[term_id] => 88
[name] => Use of background IP
[slug] => use-background-ip
[term_group] => 0
[term_taxonomy_id] => 88
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 18
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[81] => WP_Term Object
(
[term_id] => 81
[name] => Warranties
[slug] => warranties
[term_group] => 0
[term_taxonomy_id] => 81
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 3
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
)
[issues_by_slug:GHIAA2019\MapguideSearch:private] => Array
(
[access-to-medicines] => WP_Term Object
(
[term_id] => 46
[name] => Access to medicines
[slug] => access-to-medicines
[term_group] => 0
[term_taxonomy_id] => 46
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[access-results] => WP_Term Object
(
[term_id] => 91
[name] => Access to results
[slug] => access-results
[term_group] => 0
[term_taxonomy_id] => 91
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 9
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[pricing] => WP_Term Object
(
[term_id] => 100
[name] => Affordable or reasonable pricing
[slug] => pricing
[term_group] => 0
[term_taxonomy_id] => 100
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 1
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[annexes] => WP_Term Object
(
[term_id] => 55
[name] => Annexes
[slug] => annexes
[term_group] => 0
[term_taxonomy_id] => 55
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[benefit-revenue-sharing] => WP_Term Object
(
[term_id] => 66
[name] => Benefit/revenue sharing
[slug] => benefit-revenue-sharing
[term_group] => 0
[term_taxonomy_id] => 66
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 3
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[business-model] => WP_Term Object
(
[term_id] => 53
[name] => Business model
[slug] => business-model
[term_group] => 0
[term_taxonomy_id] => 53
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 1
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[commercialization-strategy] => WP_Term Object
(
[term_id] => 58
[name] => Commercialization strategy
[slug] => commercialization-strategy
[term_group] => 0
[term_taxonomy_id] => 58
[taxonomy] => issue
[description] =>
[parent] => 55
[count] => 0
[filter] => raw
[parent_name] => Annexes
[parent_slug] => annexes
)
[confidentiality] => WP_Term Object
(
[term_id] => 84
[name] => Confidentiality
[slug] => confidentiality
[term_group] => 0
[term_taxonomy_id] => 84
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 20
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[conflict-of-interest] => WP_Term Object
(
[term_id] => 59
[name] => Conflict of Interest
[slug] => conflict-of-interest
[term_group] => 0
[term_taxonomy_id] => 59
[taxonomy] => issue
[description] =>
[parent] => 54
[count] => 0
[filter] => raw
[parent_name] => Other
[parent_slug] => other
)
[consortium-structure] => WP_Term Object
(
[term_id] => 51
[name] => Consortium structure & management
[slug] => consortium-structure
[term_group] => 0
[term_taxonomy_id] => 51
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 5
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[data-material-sharing] => WP_Term Object
(
[term_id] => 95
[name] => Data & material sharing
[slug] => data-material-sharing
[term_group] => 0
[term_taxonomy_id] => 95
[taxonomy] => issue
[description] =>
[parent] => 47
[count] => 0
[filter] => raw
[parent_name] => Open sciences & open data
[parent_slug] => open-science
)
[data-management] => WP_Term Object
(
[term_id] => 82
[name] => Data management
[slug] => data-management
[term_group] => 0
[term_taxonomy_id] => 82
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 4
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[dispute-resolution] => WP_Term Object
(
[term_id] => 267
[name] => Dispute resolution
[slug] => dispute-resolution
[term_group] => 0
[term_taxonomy_id] => 267
[taxonomy] => issue
[description] =>
[parent] => 54
[count] => 1
[filter] => raw
[parent_name] => Other
[parent_slug] => other
)
[effect-of-termination] => WP_Term Object
(
[term_id] => 72
[name] => Effect of termination
[slug] => effect-of-termination
[term_group] => 0
[term_taxonomy_id] => 72
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 2
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[equitable-access] => WP_Term Object
(
[term_id] => 101
[name] => Equitable access
[slug] => equitable-access
[term_group] => 0
[term_taxonomy_id] => 101
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 13
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[exceptions-confidentiality] => WP_Term Object
(
[term_id] => 83
[name] => Exceptions and limitations to the confidentiality obligations
[slug] => exceptions-confidentiality
[term_group] => 0
[term_taxonomy_id] => 83
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 7
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[exceptions-ip-ownership] => WP_Term Object
(
[term_id] => 93
[name] => Exceptions or limitations to the IP ownership rules
[slug] => exceptions-ip-ownership
[term_group] => 0
[term_taxonomy_id] => 93
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 1
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[exploitation-results] => WP_Term Object
(
[term_id] => 92
[name] => Exploitation of results
[slug] => exploitation-results
[term_group] => 0
[term_taxonomy_id] => 92
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 9
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[funder-step-in] => WP_Term Object
(
[term_id] => 103
[name] => Funder step-in rights
[slug] => funder-step-in
[term_group] => 0
[term_taxonomy_id] => 103
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 1
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[global-access-plans] => WP_Term Object
(
[term_id] => 57
[name] => Global access plans
[slug] => global-access-plans
[term_group] => 0
[term_taxonomy_id] => 57
[taxonomy] => issue
[description] =>
[parent] => 55
[count] => 0
[filter] => raw
[parent_name] => Annexes
[parent_slug] => annexes
)
[indemnity] => WP_Term Object
(
[term_id] => 80
[name] => Indemnity / indemnification
[slug] => indemnity
[term_group] => 0
[term_taxonomy_id] => 80
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 8
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[information-sharing-information-sharing] => WP_Term Object
(
[term_id] => 257
[name] => Information sharing
[slug] => information-sharing-information-sharing
[term_group] => 0
[term_taxonomy_id] => 257
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 2
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[information-sharing] => WP_Term Object
(
[term_id] => 49
[name] => Information sharing & data safety
[slug] => information-sharing
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 3
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[insurance] => WP_Term Object
(
[term_id] => 109
[name] => Insurance
[slug] => insurance
[term_group] => 0
[term_taxonomy_id] => 109
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 1
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[ip-ownership] => WP_Term Object
(
[term_id] => 48
[name] => IP ownership & licensing
[slug] => ip-ownership
[term_group] => 0
[term_taxonomy_id] => 48
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 1
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[liability] => WP_Term Object
(
[term_id] => 50
[name] => Liability
[slug] => liability
[term_group] => 0
[term_taxonomy_id] => 50
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[limitation-of-liability] => WP_Term Object
(
[term_id] => 79
[name] => Limitation of liability/damage
[slug] => limitation-of-liability
[term_group] => 0
[term_taxonomy_id] => 79
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 10
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[material-transfer] => WP_Term Object
(
[term_id] => 85
[name] => Material transfer
[slug] => material-transfer
[term_group] => 0
[term_taxonomy_id] => 85
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 4
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[open-data] => WP_Term Object
(
[term_id] => 98
[name] => Open data
[slug] => open-data
[term_group] => 0
[term_taxonomy_id] => 98
[taxonomy] => issue
[description] =>
[parent] => 47
[count] => 8
[filter] => raw
[parent_name] => Open sciences & open data
[parent_slug] => open-science
)
[open-sciences] => WP_Term Object
(
[term_id] => 97
[name] => Open sciences
[slug] => open-sciences
[term_group] => 0
[term_taxonomy_id] => 97
[taxonomy] => issue
[description] =>
[parent] => 47
[count] => 8
[filter] => raw
[parent_name] => Open sciences & open data
[parent_slug] => open-science
)
[open-science] => WP_Term Object
(
[term_id] => 47
[name] => Open sciences & open data
[slug] => open-science
[term_group] => 0
[term_taxonomy_id] => 47
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[other] => WP_Term Object
(
[term_id] => 54
[name] => Other
[slug] => other
[term_group] => 0
[term_taxonomy_id] => 54
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[outbreak-preparedness] => WP_Term Object
(
[term_id] => 102
[name] => Outbreak preparedness
[slug] => outbreak-preparedness
[term_group] => 0
[term_taxonomy_id] => 102
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 1
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[ownership-background-ip] => WP_Term Object
(
[term_id] => 87
[name] => Ownership of background IP
[slug] => ownership-background-ip
[term_group] => 0
[term_taxonomy_id] => 87
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 8
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[ownership-results] => WP_Term Object
(
[term_id] => 89
[name] => Ownership of results
[slug] => ownership-results
[term_group] => 0
[term_taxonomy_id] => 89
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 14
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[pandemic-products] => WP_Term Object
(
[term_id] => 266
[name] => Pandemic Products
[slug] => pandemic-products
[term_group] => 0
[term_taxonomy_id] => 266
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 1
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[policy-considerations] => WP_Term Object
(
[term_id] => 104
[name] => Policy considerations
[slug] => policy-considerations
[term_group] => 0
[term_taxonomy_id] => 104
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 1
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[protection-results] => WP_Term Object
(
[term_id] => 90
[name] => Protection of results
[slug] => protection-results
[term_group] => 0
[term_taxonomy_id] => 90
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 8
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[public-health-licenses] => WP_Term Object
(
[term_id] => 107
[name] => Public health licenses
[slug] => public-health-licenses
[term_group] => 0
[term_taxonomy_id] => 107
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 2
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[publication] => WP_Term Object
(
[term_id] => 96
[name] => Publication
[slug] => publication
[term_group] => 0
[term_taxonomy_id] => 96
[taxonomy] => issue
[description] =>
[parent] => 47
[count] => 7
[filter] => raw
[parent_name] => Open sciences & open data
[parent_slug] => open-science
)
[regulatory-strategy] => WP_Term Object
(
[term_id] => 56
[name] => Regulatory strategy
[slug] => regulatory-strategy
[term_group] => 0
[term_taxonomy_id] => 56
[taxonomy] => issue
[description] =>
[parent] => 55
[count] => 0
[filter] => raw
[parent_name] => Annexes
[parent_slug] => annexes
)
[reporting] => WP_Term Object
(
[term_id] => 64
[name] => Reporting
[slug] => reporting
[term_group] => 0
[term_taxonomy_id] => 64
[taxonomy] => issue
[description] =>
[parent] => 54
[count] => 0
[filter] => raw
[parent_name] => Other
[parent_slug] => other
)
[risk-sharing] => WP_Term Object
(
[term_id] => 69
[name] => Risk sharing
[slug] => risk-sharing
[term_group] => 0
[term_taxonomy_id] => 69
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 0
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[royalties-and-payments] => WP_Term Object
(
[term_id] => 70
[name] => Royalties & payments
[slug] => royalties-and-payments
[term_group] => 0
[term_taxonomy_id] => 70
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 2
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[sublicensee] => WP_Term Object
(
[term_id] => 108
[name] => Sublicenses
[slug] => sublicensee
[term_group] => 0
[term_taxonomy_id] => 108
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 2
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[survival] => WP_Term Object
(
[term_id] => 62
[name] => Survival
[slug] => survival
[term_group] => 0
[term_taxonomy_id] => 62
[taxonomy] => issue
[description] =>
[parent] => 54
[count] => 0
[filter] => raw
[parent_name] => Other
[parent_slug] => other
)
[technology-transfer] => WP_Term Object
(
[term_id] => 86
[name] => Technology transfer
[slug] => technology-transfer
[term_group] => 0
[term_taxonomy_id] => 86
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 6
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[term-and-termination] => WP_Term Object
(
[term_id] => 52
[name] => Term & termination
[slug] => term-and-termination
[term_group] => 0
[term_taxonomy_id] => 52
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[term-of-agreement] => WP_Term Object
(
[term_id] => 76
[name] => Term of agreement
[slug] => term-of-agreement
[term_group] => 0
[term_taxonomy_id] => 76
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 4
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[termination-and-withdrawal] => WP_Term Object
(
[term_id] => 74
[name] => Termination & withdrawal
[slug] => termination-and-withdrawal
[term_group] => 0
[term_taxonomy_id] => 74
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 6
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[use-background-ip] => WP_Term Object
(
[term_id] => 88
[name] => Use of background IP
[slug] => use-background-ip
[term_group] => 0
[term_taxonomy_id] => 88
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 18
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[warranties] => WP_Term Object
(
[term_id] => 81
[name] => Warranties
[slug] => warranties
[term_group] => 0
[term_taxonomy_id] => 81
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 3
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
)
[filter_issues:GHIAA2019\MapguideSearch:private] => Array
(
)
)
